1
|
Crespi CM, Ganz PA, Partridge AH, Wolff A, Joffe H, Irwin MR, Thure K, Petersen L, Shih YCT, Bower JE. Work Productivity Among Younger Breast Cancer Survivors: The Impact of Behavioral Interventions for Depression. Value Health 2024; 27:322-329. [PMID: 38135214 DOI: 10.1016/j.jval.2023.12.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/14/2023] [Revised: 11/14/2023] [Accepted: 12/06/2023] [Indexed: 12/24/2023]
Abstract
OBJECTIVES The Pathways to Wellness randomized controlled trial found that 2 behavioral interventions, mindfulness awareness practices and survivorship education, reduced depressive symptoms in younger breast cancer survivors (BCSs) compared with wait-list control. This secondary analysis examines whether the interventions led to reduced loss of work productivity among younger BCSs and whether such reductions were mediated by reductions in depressive symptoms. METHODS The Work Productivity and Activity Impairment scale was used to measure work productivity loss at 4 assessment time points. Correlates of productivity loss at enrollment were examined using multivariable linear regression. Differences in change over time in productivity loss between each intervention group and control were assessed using linear mixed models. Reduced depressive symptoms were tested as a mediator of reduced productivity loss. RESULTS Of 247 trial participants, 199 were employed and included in the analyses. At enrollment, higher productivity loss was associated with chemotherapy receipt (P = .003), younger age (P = .021), more severe cognitive problems (P = .002), higher musculoskeletal pain severity (P = .002), more depressive symptoms (P = .016), and higher fatigue severity (P = .033). The mindfulness intervention led to significantly less productivity loss compared with control at all 3 postintervention assessment points (all P < .05), with about 54% of the effect mediated by reduction in depressive symptoms. Survivorship education was not associated with reduced loss of productivity. CONCLUSIONS These findings suggest that addressing depressive symptoms through behavioral interventions, such as mindfulness, may mitigate impacts on work productivity in younger BCSs.
Collapse
Affiliation(s)
- Catherine M Crespi
- Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA; Department of Biostatistics, UCLA Fielding School of Public Health, Los Angeles, CA, USA.
| | - Patricia A Ganz
- Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA; Department of Medicine (Hematology-Oncology), David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Department of Health Policy & Management, UCLA Fielding School of Public Health, Los Angeles, CA, USA
| | - Ann H Partridge
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA
| | - Antonio Wolff
- The Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
| | - Hadine Joffe
- Connors Center for Women's Health and Gender Biology, Brigham and Women's Hospital Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Department of Psychiatry, Brigham and Women's Hospital, Boston, MA, USA; Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Boston, MA, USA
| | - Michael R Irwin
- Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA; Department of Psychology, University of California Los Angeles, Los Angeles, CA, USA; Cousins Center for Psychoneuroimmunology, Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA, USA
| | - Katie Thure
- David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
| | - Laura Petersen
- Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA
| | - Ya-Chen Tina Shih
- Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA; Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Julienne E Bower
- Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA; Department of Psychology, University of California Los Angeles, Los Angeles, CA, USA; Cousins Center for Psychoneuroimmunology, Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA, USA
| |
Collapse
|
2
|
Henderson NL, Andrews C, Ingram SA, Zubkoff L, Tung N, Wagner LI, Wallner LP, Wolff A, Rocque GB. "Clinical trials are space travel": Factors of psychological response to recurrence among oncologists enrolling patients in treatment optimization trials. Cancer Med 2023; 12:21490-21501. [PMID: 37947134 PMCID: PMC10726815 DOI: 10.1002/cam4.6710] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2023] [Revised: 08/17/2023] [Accepted: 10/26/2023] [Indexed: 11/12/2023] Open
Abstract
BACKGROUND Cancer recurrence after treatment is a concern for patients and oncologists alike. The movement towards treatment optimization, with trials testing less than the current standard of care (SoC), complicates this experience. Our objective was to assess oncologists' psychological response to patient recurrence on optimization-focused trials and identify factors that influence those experiences. METHODS Clinical oncologists participated in a semi-structured interview regarding patient enrollment in treatment optimization trials. We identified factors that influence the degree of psychological response that the oncologist may feel after patient recurrence. Residual agreement analysis was used to identify whether differences in reported psychological response was associated with alternative emphases on identified factors. RESULTS Thirty-six oncologists identified 20 factors spanning five major themes that affected their psychological response to patient recurrence. All oncologists expressed willingness to enroll patients in treatment optimization clinical trials; however, half indicated that they were more likely to experience a negative psychological response after a treatment optimization trial than after a traditional intensification trial, and a quarter reported that patient recurrence on an optimization trial would impact their recommendations for future trial enrollment. Oncologists who reported more negative psychological responses to patient recurrence after participation in an optimization trial were more likely to emphasize introspective factors, while those who reported no difference in response emphasized patient- and process-focused factors. CONCLUSIONS Although most oncologists recognize the importance of treatment optimization trials, a significant proportion indicated a greater potential for psychological distress following patient recurrence in such trials and offered insight into how trial design and the process of patient enrollment can be improved to minimize those negative psychological responses.
Collapse
Affiliation(s)
| | - Courtney Andrews
- University of Alabama at Birmingham Heersink School of MedicineBirminghamAlabamaUSA
| | - Stacey A. Ingram
- University of Alabama at Birmingham Heersink School of MedicineBirminghamAlabamaUSA
| | - Lisa Zubkoff
- University of Alabama at Birmingham Heersink School of MedicineBirminghamAlabamaUSA
- GRECC, Birmingham Virginia Healthcare SystemBirminghamAlabamaUSA
| | - Nadine Tung
- Beth Israel Deaconess Medical CenterBostonMassachusettsUSA
| | - Lynne I. Wagner
- Department of Social Sciences and Health PolicyWake Forest University Health SciencesWinston‐SalemNorth CarolinaUSA
| | | | | | - Gabrielle B. Rocque
- University of Alabama at Birmingham Heersink School of MedicineBirminghamAlabamaUSA
| |
Collapse
|
3
|
Rhome R, Wright J, De Souza Lawrence L, Stearns V, Wolff A, Zellars R. Concurrent chemotherapy with partial breast irradiation in triple negative breast cancer patients may improve disease control compared with sequential therapy. Front Oncol 2023; 13:1146754. [PMID: 37503312 PMCID: PMC10370352 DOI: 10.3389/fonc.2023.1146754] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2023] [Accepted: 06/06/2023] [Indexed: 07/29/2023] Open
Abstract
Purpose To report outcomes on a subset of patients with triple negative breast cancer (TNBC) treated on prospective trials with post-lumpectomy partial breast irradiation and concurrent chemotherapy (PBICC) and compare them to a retrospectively assessed similar cohort treated with whole breast irradiation after adjuvant chemotherapy (WBIaC). Methods and materials Women with T1-2, N0-1 invasive breast cancer with ≥ 2mm lumpectomy margins were offered therapy on one of two PBICC trials. PBI consisted of 40.5 Gy in 15 daily 2.7 Gy fractions delivered concurrently with the first 2 cycles of adjuvant chemotherapy. The comparison cohort received WBI to a median dose of 60.7 Gy, (including boost, range 42.5 - 66 Gy), after completion of non-concurrent, adjuvant chemotherapy. We evaluated disease-free survival (DFS), and local/loco-regional/distant recurrence-free survival (RFS). We compared survival rates using Kaplan-Meier curves and log-rank test of statistical significance. Results Nineteen patients with TNBC were treated with PBICC on prospective protocol, and 49 received WBIaC. At a median follow-up of 35.5 months (range 4.8-71.9), we observed no deaths in the PBICC cohort and 2 deaths in the WBIaC cohort (one from disease recurrence). With a median time of 23.4 (range 4.8 to 47) months, there were 7 recurrences (1 nodal, 4 local, 4 distant), all in the WBIaC group. At 5 years, there was a trend towards increased local RFS (100% vs. 85.4%, p=0.17) and loco-regional RFS (100% vs. 83.5, p=0.13) favoring the PBICC cohort. There was no significant difference in distant RFS between the two groups (100% vs. 94.4%, p=0.36). Five-year DFS was 100% with PBICC vs.78.9% (95% CI: 63.2 to 94.6%, p=0.08) with WBIaC. Conclusion This study suggests that PBICC may offer similar and possibly better outcomes in patients with TNBC compared to a retrospective cohort treated with WBIaC. This observation is hypothesis-generating for prospective trials.
Collapse
Affiliation(s)
- Ryan Rhome
- Department of Radiation Oncology, Indiana University Hospital, Indianapolis, IN, United States
| | - Jean Wright
- Department of Radiation Oncology, The Johns Hopkins Hospital, Johns Hopkins Medicine, Baltimore, MD, United States
| | | | - Vered Stearns
- Department of Oncology, Division of Women’s Malignancies, The Johns Hopkins Hospital, Johns Hopkins Medicine, Baltimore, MD, United States
| | - Antonio Wolff
- Department of Oncology, Division of Women’s Malignancies, The Johns Hopkins Hospital, Johns Hopkins Medicine, Baltimore, MD, United States
| | - Richard Zellars
- Department of Radiation Oncology, Indiana University Hospital, Indianapolis, IN, United States
| |
Collapse
|
4
|
Wolff A, Münstermann N, Pretzer J, Redecker A, Jud T, Böthig R. [The neuro-urological expert opinion in statutory accident insurance : Consensual recommendations for diagnostics and for the assessment of reduction of earning capacity]. Urologie 2023; 62:229-240. [PMID: 36867214 PMCID: PMC9998578 DOI: 10.1007/s00120-023-02039-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Accepted: 01/17/2023] [Indexed: 06/18/2023]
Abstract
BACKGROUND Previous assessment guidelines from standard sources for urologic expert opinions show considerable differences in the recommended percentages for the assessment of reduction of earning capacity (MdE) for accident sequelae in the neuro-urological specialty. OBJECTIVES To develop a "revised and standardized version of the MdE assessments of neuro-urological accident sequelae (in tabular form) as a guideline/manual" for expert opinions in the legal area of the German and Austrian Statutory Accident Insurance ( www.dguv.de , www.auva.at ). MATERIALS AND METHODS A working group of neuro-urologists from spinal cord injury centers of different BG ("Berufsgenossenschaft") clinics was formed within the working group Neuro-Urology of DMGP (German-speaking Medical Society for Paraplegiology; www.dmgp.de ). Between January 2017 and September 2022, a total of 7 working meetings and 2 video conferences were held. The consensus of the developed documents was reached by formal consensus finding in a nominal group process and in a final consensus conference. RESULTS The necessary bases for a targeted, legally sound diagnosis of accident consequences in the neuro-urological field were elaborated and, based on the experience of many years of expert opinion activity, a "matrix" for a uniform, graduated assessment of the level of reduction of earning capacity in the (neuro-)urological field in the case of confirmed neuro-urological accident consequences was created. CONCLUSION In the interest of equal treatment of all insured persons, it is of great importance to make a uniform and comprehensible assessment of the amount of the MdE on the basis of "table values" that reflect the available empirical values.
Collapse
Affiliation(s)
- A Wolff
- Abteilung Neuro-Urologie, BG-Unfallklinik Murnau, Professor-Küntscher-Str. 8, 82418, Murnau, Deutschland.
| | | | - J Pretzer
- BG Unfallkrankenhaus Berlin, Berlin, Deutschland
| | - A Redecker
- Bergmannstrost BG Klinikum Halle, Halle, Deutschland
| | - T Jud
- AUVA Rehabilitationszentrum Häring, Bad Häring, Österreich
| | - R Böthig
- BG Klinikum Hamburg, Hamburg, Deutschland
| |
Collapse
|
5
|
Imam S, Carpenter T, Wolff A, Khianey R, Capitle E. MRNA COVID-19 VACCINE-ASSOCIATED BULLOUS FIXED DRUG ERUPTION. Ann Allergy Asthma Immunol 2022. [PMCID: PMC9646440 DOI: 10.1016/j.anai.2022.08.764] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Introduction Fixed drug eruptions are unique cutaneous drug reactions that recur in the same location upon re-exposure to the offending agent. We report a dilemma of how to proceed with the vaccination after a rare complication of the mRNA covid-19 vaccine. Case Description A 47-year-old female referred to us after developing a rash to the mRNA covid-19 vaccine for evaluation of safety and plan on how to proceed with the booster vaccine. After the 1st dose on her left deltoid, she developed persistent right arm pruritus from mid-forearm to wrist that gradually became well-demarcated and erythematous by day four. Rash improved within seven days of using hydrocortisone but left hyperpigmentation of the skin. Two weeks after receiving her 2nd dose on her left deltoid, the same location on her right forearm flared up with more pronounced pruritus, erythema and a few bullous lesions. Rash improved after a week of using hydrocortisone leaving behind hyperpigmentation. The patient denied using any prior medications and had no other skin or mucosal involvement. We decided to proceed with another brand of mRNA covid-19 vaccine instead and prophylactically apply clobetasol twice daily to the affected area for 7-days post-vaccine. She tolerated the vaccine without any flare-up of the rash. Discussion Fixed drug eruptions more frequently occur with drugs including antimicrobials, NSAIDs, acetaminophen and anti-convulsants. Very rarely has it been reported in association with the administration of the Covid-19 vaccines. This case illustrates a unique predicament after an unusual complication of bullous fixed drug eruption after mRNA covid-19 vaccine administration.
Collapse
|
6
|
Gruene B, Kugler S, Kuefer-Weiß A, Wolff A, Kossow A, Nießen J, Neuhann F, Ginzel S, Buess M. Public Health benefits by implementing digital symptom diaries for COVID patients from Cologne. Eur J Public Health 2022. [PMCID: PMC9594271 DOI: 10.1093/eurpub/ckac131.049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
Background High rate of people infected with SARS-CoV-2 and their contacts in Cologne, Germany required innovative tools for notification, monitoring and reporting. The digital tool for COVID19 (DiKoMa) provides self-service symptom diaries allowing (a) the stratification for prioritized telephone contact by the health authority and (b) training a machine learning (ML) model that predicts infections with prevailing dominant variant (PDV) from early symptom profiles (SP). Methods Pseudononymized SP covering the first week of diary recordings were included for training (16646 index, 11582 contacts). A balanced random forest (BRF) model was trained to differentiate early predictive symptom patterns of different PDV and contact persons. Model evaluation was performed using sex and age stratified cross validation (CV), the model was validated on SP recorded from days 1 and 6. Results From 03/20 to 02/22, 90478 indeces and 75444 contact persons reported symptoms and health status, covering 46% and 42% of all reported cases, respectively. Diaries contained between 1-52 entries (566791, median 2). Daily analysis of entries, prioritized according to age, prevalent co-morbidities and detoriation of symptoms allowed risk adjusted follow up even during phases with high case notification rates. The top 5 predictive factors of the BRF were immunization, cough, dysgeusia and dysnosmia, fatigue, and sniffles to differentiate infection between wildtype, three PDV and contact persons (CV AUC 80.6%, Validation AUC 77.1%). Conclusions The use of digital symptom diary surveillance helps to provide appropriate medical support for patients on a large scale. Machine learning shows potential for symptom based risk assessment to differentiate PDV for future outbreaks and can thus become a valuable tool alongside specific laboratory diagnostics. Key messages • Digital symptom diaries are a powerful and widely accepted tool to attend COVID19 patients in isolation. They allow risk stratification for follow up and are a low-threshold service. • Machine learning supports index case identification by symptom analysis and can thus become a valuable tool alongside specific laboratory diagnostics.
Collapse
Affiliation(s)
- B Gruene
- Health Department Cologne , Cologne, Germany
| | - S Kugler
- Fraunhofer Institute for Intelligent Analysis , Sankt Augustin, Germany
| | | | - A Wolff
- Health Department Cologne , Cologne, Germany
| | - A Kossow
- Health Department Cologne , Cologne, Germany
- Institut for Hygiene, University of Muenster , Muenster, Germany
| | - J Nießen
- Health Department Cologne , Cologne, Germany
| | - F Neuhann
- Health Department Cologne , Cologne, Germany
- Institut for Global Health, University of Heidelberg , Heidelberg, Germany
| | - S Ginzel
- Fraunhofer Institute for Intelligent Analysis , Sankt Augustin, Germany
| | - M Buess
- Health Department Cologne , Cologne, Germany
| |
Collapse
|
7
|
Arboleda B, Bartsch R, de Azambuja E, Hamilton E, Harbeck N, Klemp J, Knauer M, Kuemmel S, Mahtani R, Schwartzberg L, Villarreal-Garza C, Wolff A. Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel. Oncologist 2022; 27:722-731. [PMID: 35704278 PMCID: PMC9438910 DOI: 10.1093/oncolo/oyac101] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2021] [Accepted: 04/26/2022] [Indexed: 01/07/2023] Open
Abstract
It has been suggested that the benefit of adjuvant chemotherapy (CT) in premenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) early breast cancer may be related, at least in part, to CT-induced ovarian function suppression (OFS) in this subgroup of patients. Although this hypothesis has not been directly tested in large randomized clinical trials, the observations from prospective studies have been remarkably consistent in showing a late benefit of CT among the subgroup of patients who benefit (ie, women who were close to menopause). The hypothesis has important clinical implications, as it may be possible to spare the associated adverse effects of adjuvant CT in a select group of women with early breast cancer, in favor of optimizing OFS and endocrine therapy (ET), without compromising clinical outcomes. Such an approach has the added benefit of preserving the key quality of life outcomes in premenopausal women, particularly by preventing the irreversible loss of ovarian function that may result from CT use. For this reason, we convened an international panel of clinical experts in breast cancer treatment to discuss the key aspects of the available data in this area, as well as the potential clinical implications for patients. This article summarizes the results of these discussions and presents the consensus opinion of the panel regarding optimizing the use of OFS for premenopausal women with HR+, HER2- early breast cancer.
Collapse
Affiliation(s)
- Bolivar Arboleda
- Puerto Rican Society of Mastology, HIMA San Pablo Oncology Hospital, Caguas, Puerto Rico
| | - Rupert Bartsch
- Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria
| | | | - Erika Hamilton
- Breast and Gynecologic Research Program, Sarah Cannon Research Institute, Tennessee Oncology PLLC, Nashville, TN, USA
| | - Nadia Harbeck
- LMU Munich, University Hospital, Department of Obstetrics and Gynecology, Breast Center and Comprehensive Cancer Center (CCLMU), Munich, Germany
| | - Jennifer Klemp
- University of Kansas Cancer Center, Kansas City, KS, USA
| | - Michael Knauer
- Department of Pathology and Laboratory Medicine, Western University and London Health Sciences Centre, London, ON, Canada
| | - Sherko Kuemmel
- Department of Gynecology with Breast Center, Charité-Universitätsmedizin Berlin, Germany
| | | | | | - Cynthia Villarreal-Garza
- Breast Cancer Center, Hospital Zambrano Hellion, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico
| | - Antonio Wolff
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
| |
Collapse
|
8
|
Wright JL, Rahbar H, Obeng-Gyasi S, Carlos R, Tjoe JA, Wolff A. Reply to I. Jatoi. J Clin Oncol 2022; 40:1595-1596. [PMID: 35245080 DOI: 10.1200/jco.22.00220] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Jean L Wright
- Jean L. Wright, MD, Johns Hopkins University, Baltimore, MD; Habib Rahbar, MD, University of Washington, Seattle, WA; Samilia Obeng-Gyasi, MD, The Ohio State University, Columbus, OH; Ruth Carlos, MD, University of Michigan, Ann Arbor, MI; Judy A. Tjoe, MD, Novant Health, Greensboro, NC; and Antonio Wolff, MD, Johns Hopkins University, Baltimore, MD
| | - Habib Rahbar
- Jean L. Wright, MD, Johns Hopkins University, Baltimore, MD; Habib Rahbar, MD, University of Washington, Seattle, WA; Samilia Obeng-Gyasi, MD, The Ohio State University, Columbus, OH; Ruth Carlos, MD, University of Michigan, Ann Arbor, MI; Judy A. Tjoe, MD, Novant Health, Greensboro, NC; and Antonio Wolff, MD, Johns Hopkins University, Baltimore, MD
| | - Samilia Obeng-Gyasi
- Jean L. Wright, MD, Johns Hopkins University, Baltimore, MD; Habib Rahbar, MD, University of Washington, Seattle, WA; Samilia Obeng-Gyasi, MD, The Ohio State University, Columbus, OH; Ruth Carlos, MD, University of Michigan, Ann Arbor, MI; Judy A. Tjoe, MD, Novant Health, Greensboro, NC; and Antonio Wolff, MD, Johns Hopkins University, Baltimore, MD
| | - Ruth Carlos
- Jean L. Wright, MD, Johns Hopkins University, Baltimore, MD; Habib Rahbar, MD, University of Washington, Seattle, WA; Samilia Obeng-Gyasi, MD, The Ohio State University, Columbus, OH; Ruth Carlos, MD, University of Michigan, Ann Arbor, MI; Judy A. Tjoe, MD, Novant Health, Greensboro, NC; and Antonio Wolff, MD, Johns Hopkins University, Baltimore, MD
| | - Judy A Tjoe
- Jean L. Wright, MD, Johns Hopkins University, Baltimore, MD; Habib Rahbar, MD, University of Washington, Seattle, WA; Samilia Obeng-Gyasi, MD, The Ohio State University, Columbus, OH; Ruth Carlos, MD, University of Michigan, Ann Arbor, MI; Judy A. Tjoe, MD, Novant Health, Greensboro, NC; and Antonio Wolff, MD, Johns Hopkins University, Baltimore, MD
| | - Antonio Wolff
- Jean L. Wright, MD, Johns Hopkins University, Baltimore, MD; Habib Rahbar, MD, University of Washington, Seattle, WA; Samilia Obeng-Gyasi, MD, The Ohio State University, Columbus, OH; Ruth Carlos, MD, University of Michigan, Ann Arbor, MI; Judy A. Tjoe, MD, Novant Health, Greensboro, NC; and Antonio Wolff, MD, Johns Hopkins University, Baltimore, MD
| |
Collapse
|
9
|
Murthy RK, O'Brien B, Berry DA, Singareeka-Raghavendra A, Monroe MG, Johnson J, White J, Childress J, Sanford J, Schwartz-Gomez J, Melisko M, Morikawa A, Ferguson S, de Groot JF, Krop I, Valero V, Rimawi M, Wolff A, Tripathy D, Lin NU, Stringer-Reasor E. Abstract PD4-02: Safety and efficacy of a tucatinib-trastuzumab-capecitabine regimen for treatment of leptomeningeal metastasis (LM) in HER2-positive breast cancer: Results from TBCRC049, a phase 2 non-randomized study. Cancer Res 2022. [DOI: 10.1158/1538-7445.sabcs21-pd4-02] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Treatment options for patients (pts) with leptomeningeal metastasis (LM) are limited, and the prognosis is poor (median overall survival (OS) ~ 4-5 months). Tucatinib is a potent and highly selective HER2-targeted tyrosine kinase inhibitor approved for use in combination with trastuzumab and capecitabine in pts with metastatic HER2+ breast cancer who have received ≥1 prior HER2-based regimen in the metastatic setting, including pts with brain metastases. TBCRC049 (NCT03501979) is an investigator-initiated, phase 2, single-arm study evaluating the safety and efficacy of tucatinib, trastuzumab and capecitabine in HER2+ breast cancer with newly diagnosed LM. We have previously demonstrated therapeutic levels of tucatinib in CSF in pts with HER2+ LM (Stringer-Reasor et al, ASCO 2021). We now report efficacy outcomes of the study. Methods: Eligible pts were adults with HER2+ metastatic breast cancer, Karnofsky performance status (KPS) > 50, and newly diagnosed, untreated LM (defined as positive CSF cytology and/or radiographic evidence of LM, plus clinical signs/symptoms). Pts with treated or concurrent/new brain metastases were allowed. Pts received tucatinib 300 mg orally twice daily starting with cycle 1, day 1 (C1D1); capecitabine 1000 mg/m2 orally twice daily on days 1-14 of a 21-day cycle, starting on C1D1; and trastuzumab loading dose of 8 mg/kg IV on C1D1, and then 6 mg/kg IV once every 21 days, starting with C2D1. The primary endpoint was OS. Planned enrollment was 30 pts; however, due to lack of accrual since the FDA approval of tucatinib (4/2020), the study was closed after 17 patients were enrolled. Results: Baseline disease characteristics at LM diagnosis are shown in Table 1. Eight pts (47%) had abnormal CSF cytology (positive or equivocal). All pts had MRI evidence of LM in the brain, and 14/17 (82%) had brain metastases, of which 11 (65%) had received prior treatment for brain metastases. Median age at study treatment initiation was 53 years. Median number of treatment cycles received was 5 (range: 2-27). Median OS time was 11.9 months (95% CI: 4.1, NR). At data cutoff (6/22/21), 7/17 pts (41%) remained alive and median followup was 17 months(8-26). Median time to CNS progression was 6.9 months (95% CI: 2.8, 13.8). Conclusions: In pts with LMD from HER2+ metastatic breast cancer who were treated with tucatinib, trastuzumab, and capecitabine, the median OS time was nearly 1 year. This is the first prospective evidence of clinical benefit with a systemic regimen for HER2+ LM. Further studies evaluating brain-penetrant oral drugs in this rare pt population are needed.
Baseline Disease Characteristics (N=17)Number%Baseline CSF cytologyPositive529%Negative847%Equivocal318%None obtained1*6%Symptoms attributable to LMDYes1588%No212%MRI evidence of LMDBrain only1165%Brain and Spine635%History of brain metastasisYes1482%Prior treatment1165%New/concurrent diagnosis – no prior treatment318%No318%Extra-CNS DiseaseYes1165%No635%*One patient had VP shunt and difficulty sampling fluid; all CSF sent for research PK and non-PK studies
Citation Format: Rashmi K Murthy, Barbara O'Brien, Donald A Berry, Akshara Singareeka-Raghavendra, Maria Gule Monroe, Jason Johnson, Jason White, Jennifer Childress, Justin Sanford, Jill Schwartz-Gomez, Michelle Melisko, Aki Morikawa, Sherise Ferguson, John F de Groot, Ian Krop, Vicente Valero, Mothaffar Rimawi, Antonio Wolff, Debu Tripathy, Nancy U Lin, Erica Stringer-Reasor. Safety and efficacy of a tucatinib-trastuzumab-capecitabine regimen for treatment of leptomeningeal metastasis (LM) in HER2-positive breast cancer: Results from TBCRC049, a phase 2 non-randomized study [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr PD4-02.
Collapse
Affiliation(s)
| | | | - Donald A Berry
- University of Texas MD Anderson Cancer Center, Houston, TX
| | | | | | - Jason Johnson
- University of Texas MD Anderson Cancer Center, Houston, TX
| | - Jason White
- University of Texas MD Anderson Cancer Center, Houston, TX
| | | | - Justin Sanford
- University of Texas MD Anderson Cancer Center, Houston, TX
| | | | | | | | | | | | - Ian Krop
- Dana-Farber Cancer Center, Boston, MA
| | - Vicente Valero
- University of Texas MD Anderson Cancer Center, Houston, TX
| | | | | | - Debu Tripathy
- University of Texas MD Anderson Cancer Center, Houston, TX
| | | | - Erica Stringer-Reasor
- University of Alabama at Birmingham O’Neal Comprehensive Cancer Center, Birmingham, AL
| |
Collapse
|
10
|
Shinn E, Zahrieh D, DeMichele A, Zdenkowski N, Lemieux J, Mao J, Bjelic-Radisic V, Naughton M, Pfeiler G, Gelmon K, Mayer I, Egle D, Zoppoli G, Traina T, Jiménez MM, Novoa SA, Haddad T, Chan A, Ring AE, Wolff A, Lorenzo JJ, Sabanathan D, Burstein H, Nowecki ZI, Pristauz-Telsnigg G, Brufsky A, Bellet-Ezquerra M, Foukakis T, Novik Y, Rubovszky G, Muehlbacher K, Metzger O, Goulioti T, Law E, Partridge A, Carey L, Zoroufy A, Hlauschek D, Fesl C, Mayer E, Gnant M. Abstract P4-12-01: Adherence with adjuvant endocrine therapy with or without Palbociclib in the PALLAS trial. Cancer Res 2022. [DOI: 10.1158/1538-7445.sabcs21-p4-12-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: As the development and use of oral anticancer agents increases, it is critical to understand patient adherence to both standard and investigational agents. The open label, phase 3 multicenter PALLAS trial investigates whether adding 2 years of the CDK4/6 inhibitor palbociclib (P) to adjuvant endocrine therapy (ET) improves invasive disease-free survival (iDFS) over adjuvant ET alone in patients (pts) with HR- positive, HR2-negative, stage II-III breast cancer. Pts were randomly assigned to either Palbociclib (125 mg/day, 3 weeks on, 1 week off, in a 28-day cycle) plus ongoing provider/patient-choice adjuvant ET (P+ET) versus ET alone. We examined patient-reported adherence to ET +/- P during the first two years of study treatment. Methods: Adherence outcomes were measured in English-speaking pts in the U.S., UK, Ireland and Australia, Spanish-speaking pts in Spain and Mexico, and German-speaking pts in Germany and Austria. Adherence measures included drug diaries completed at each cycle, pill counts (for P only) collected at each study visit, and the Morisky Medication Adherence Scale-4 item and the McHorney Adherence Estimator questionnaires completed at cycles 2, 3, 6, 12, 18, and 24 (22 months). Mean adherence for each cycle was defined as the average proportion of prescribed pills taken (via drug diary) across all patients who initiated that cycle. Persistence was defined as the duration of drug initiation to treatment cessation (via drug diary). Generalized estimating equations were used to model the “most adherent” pts on the Morisky (score = 5 vs score <5) and “low risk” for adherence problems on the McHorney (score=0 vs score >0) to compare the average difference between arms over time for ET, adjusting for baseline demographic and clinical variables. Results: 81% (N=4688) of PALLAS pts were included in this analysis. Median persistence to ET was 23.6 months in P + ET (n=2169), 23.7 months in ET alone (2136) and 20.4 months for P (n=2194). The number of pts who initiated each cycle for ET declined over time and was similar between arms; the decline was more marked for P (Table 1). Mean adherence range as measured by drug diary was 98.2-99.3% for ET in P+ET and 98.0 - 99.4% in ET alone; and for P, ranged from 93.4 - 98.8%. The adherence and persistence results were nearly identical whether measured by drug diary or pill count for P. The observed percent “most adherent” for P measured by the Morisky scale ranged from 71.9% - 79.6% and the percent “low risk” for adherence problems measured by the McHorney scale, 64.0% - 73.4%. The percent of pts “most adherent” and “low risk” for adherence problems to ET was higher, on average over time, in the P+ET group compared to ET alone (75% vs 68%, p<0.01; 75% vs 72%, p=.05, respectively). Conclusions: Self-reported mean adherence for both P + ET and ET alone was strikingly high for pts who remained on therapy; persistence was also high with ET during the 2-year treatment period. Current analyses suggest that nonadherence to either P or ET was likely not a major contributor to the iDFS results seen in the overall PALLAS trial. These results illustrate the importance of measuring and monitoring patient adherence to oral study agents. Support: AFT, Pfizer; ClinicalTrials.gov (NCT02513394) and EudraCT (2014-005181-30). https://acknowledgments.alliancefound.org
Table 1.Adherence and persistence in PALLAS over the 24 month treatment periodPalbocicilb + ETETPalbociclibETETTreatment cycleMean Adherence (SD)N*Mean Adherence (SD)NMean Adherence (SD)N193.4 (13.8)229098.7 (6.1)230999.0 (5.2)2343294.7 (13.3)218198.8 (6.4)220398.4 (7.1)2206397.4 (10.1)211298.7 (7.3)214298.8 (6.3)2168497.6 (10.2)203598.6 (7.8)211099.0 (5.7)2154597.6 (11.1)197598.3 (7.9)209398.1 (8.3)2148698.1 (8.7)189998.7 (6.6)203798.5 (8.2)2116798.1 (9.3)185599.0 (6.3)201298.6 (7.3)2102898.0 (9.1)181098.2 (8.2)199798.1 (8.2)2092998.4 (7.4)173399.0 (6.4)196298.8 (6.8)20511098.3 (8.6)171499.2 (4.9)194699.0 (5.5)20381198.3 (8.0)169198.5 (7.3)193798.2 (8.2)20311298.7 (6.2)161299.1 (5.3)191098.7 (7.5)19861398.5 (7.7)159698.9 (6.4)189398.8 (7.1)19691497.9 (9.3)157698.4 (7.3)188298.0 (9.1)19611598.5 (6.9)151499.2 (4.6)185499.0 (6.0)19281698.2 (8.7)148699.1 (4.6)183599.1 (5.7)19131798.1 (9.8)147998.3 (7.8)182698.5 (6.4)19031898.7 (6.8)141699.3 (4.1)176899.2 (5.3)18601998.7 (7.3)140899.3 (3.8)175699.4 (3.1)18482098.4 (8.9)139798.9 (5.3)174298.7 (5.8)18382198.5 (7.5)130199.0 (6.1)167698.8 (7.1)17842297.8 (9.7)124698.8 (6.2)164799.2 (5.7)17692398.1 (8.8)118098.2 (8.5)161998.4 (8.0)17552498.8 (7.2)108699.0 (6.3)146898.9 (7.1)16192598.8 (6.7)99699.2 (5.2)143298.8 (7.1)15892697.9 (11.2)84599.1 (5.7)140998.6 (8.8)1578ET=Endocrine therapy * Number of pts who initiated the treatment cycle.
Citation Format: Eileen Shinn, David Zahrieh, Angela DeMichele, Nick Zdenkowski, Julie Lemieux, Jun Mao, Vesna Bjelic-Radisic, Michelle Naughton, Georg Pfeiler, Karen Gelmon, Ingrid Mayer, Daniel Egle, Gabriele Zoppoli, Tiffany Traina, Miguel Martin Jiménez, Silvia Antolin Novoa, Tufia Haddad, Arlene Chan, Alistair Edward Ring, Antonio Wolff, Jose JuanPonce Lorenzo, Dhanusha Sabanathan, Hal Burstein, Zbigniew Ireneusz Nowecki, Gunda Pristauz-Telsnigg, Adam Brufsky, Meritxell Bellet-Ezquerra, Theodoros Foukakis, Yelena Novik, Gabor Rubovszky, Karoline Muehlbacher, Otto Metzger, Theodora Goulioti, Ernest Law, Ann Partridge, Lisa Carey, Alex Zoroufy, Dominik Hlauschek, Christian Fesl, Erica Mayer, Michael Gnant. Adherence with adjuvant endocrine therapy with or without Palbociclib in the PALLAS trial [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P4-12-01.
Collapse
Affiliation(s)
| | | | | | | | | | - Jun Mao
- Memorial Sloan Kettering Cancer Center/AFT, New York, NY
| | - Vesna Bjelic-Radisic
- Helios University Clinic Wuppertal, Breast Unit University Witten/Herdecke, Wuppertal, Germany
| | | | - Georg Pfeiler
- Austrian Breast Cancer Study Group (ABCSG), Vienna, Austria
| | - Karen Gelmon
- University of British Columbia, Vancouver, BC, Canada
| | | | - Daniel Egle
- Medical University Innsbruck, Innsbruck, Austria
| | - Gabriele Zoppoli
- University Hospital San Martino - National Cancer Institute, Genoa, Italy
| | - Tiffany Traina
- Memorial Sloan Kettering Cancer Center/AFT, New York, NY
| | | | | | | | - Arlene Chan
- Breast Cancer Research Centre-WA, Nedlands, WA, Australia
| | | | | | | | - Dhanusha Sabanathan
- Lakeside Specialist Breast Clinic and Nepean Cancer Care Centre, Norwest, NSW, Australia
| | - Hal Burstein
- Dana-Farber Cancer Institute/Alliance, Boston, MA
| | | | | | - Adam Brufsky
- University of Pittsburgh Cancer Institute, Pittsburgh, PA
| | | | | | | | | | | | - Otto Metzger
- Dana-Farber Cancer Institute/Alliance, Boston, MA
| | | | | | | | - Lisa Carey
- University of North Carolina/Alliance, Chapel Hill, NC
| | | | | | - Christian Fesl
- Austrian Breast Cancer Study Group (ABCSG), Vienna, Austria
| | - Erica Mayer
- Dana-Farber Cancer Institute/AFT, Boston, MA
| | - Michael Gnant
- Medical University of Vienna, ABCSG, Vienna, Austria
| |
Collapse
|
11
|
Zafar S, Wolff A. M225 A RARE CASE OF EOSINOPHILIC GASTROENTERITIS. Ann Allergy Asthma Immunol 2021. [DOI: 10.1016/j.anai.2021.08.354] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
12
|
Smith KC, White S, DeSanto J, Hannum S, Mayonado N, Ahuja N, Bowie J, Cowall D, Mischtschuk J, Peairs K, Thorner E, Tran P, Wolff A, Snyder C. Implementing survivorship care planning in two contrasting health systems: lessons learned from a randomized controlled trial. J Cancer Surviv 2021; 16:791-800. [PMID: 34296383 DOI: 10.1007/s11764-021-01073-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2021] [Accepted: 06/05/2021] [Indexed: 11/24/2022]
Abstract
OBJECTIVE Survivorship care plans (SCPs) are recommended to promote appropriate follow-up care, but implementation has been limited. We conducted a randomized controlled trial comparing three SCP delivery models in two health systems. We utilize mixed methods to compare the feasibility and participants' perceived value of the three models. METHODS Patients completing treatment for stage I-III breast, prostate, or colorectal cancer from one urban-academic and one rural community cancer center were randomized to (1) mailed SCP, (2) SCP delivered during an in-person survivorship visit, or (3) SCP delivered during an in-person survivorship visit plus 6-month follow-up. Clinics had flexibility in intervention implementation. Quantitative data summarize intervention fidelity and protocol deviations. Qualitative interview data provide patients' perspectives on feasibility and intervention value. RESULTS Of 475 eligible participants approached, 378 (79%) were randomized. Of 345 SCPs delivered, 265 (76.8%) were by protocol. Protocol deviations were more common at the urban-academic center. In post-study qualitative interviews, participants recalled little about the SCP document or visit(s). SCPs were valued for information and care coordination, although their static nature was limiting, and sometimes SCP information differed from that provided elsewhere. Visits were opportunities for care and reassurance, but time and distance to the clinic were barriers. CONCLUSIONS SCP provision was challenging. Patients were interested in SCP, but not necessarily additional survivorship visits, particularly at the urban-academic hospital. IMPLICATIONS FOR CANCER SURVIVORS These findings suggest that patients value careful consideration of health care needs during the transition out of treatment; SCP documents are one element of this. For many patients, models without additional visits and dynamic SCPs may be preferred.
Collapse
Affiliation(s)
- Katherine C Smith
- Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA. .,Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA. .,Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, 624 N. Broadway Rm 726, Baltimore, MD, 21215, USA.
| | - Sharon White
- Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA
| | - Jennifer DeSanto
- Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA
| | - Susan Hannum
- Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA
| | - Nancy Mayonado
- Tidal Health Richard A. Henson Research Institute, Salisbury, MD, USA
| | - Nita Ahuja
- Yale University Department of Surgery, New Haven, CT, USA
| | - Janice Bowie
- Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA
| | - David Cowall
- Tidal Health Richard A. Henson Research Institute, Salisbury, MD, USA
| | - Joan Mischtschuk
- Tidal Health Richard A. Henson Research Institute, Salisbury, MD, USA
| | | | - Elissa Thorner
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
| | - Phuoc Tran
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.,Johns Hopkins School of Medicine, Baltimore, MD, USA
| | - Antonio Wolff
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.,Johns Hopkins School of Medicine, Baltimore, MD, USA
| | - Claire Snyder
- Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.,Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.,Johns Hopkins School of Medicine, Baltimore, MD, USA
| |
Collapse
|
13
|
Houmøller SS, Wolff A, Möller S, Narne VK, Narayanan SK, Godballe C, Hougaard DD, Loquet G, Gaihede M, Hammershøi D, Schmidt JH. Prediction of successful hearing aid treatment in first-time and experienced hearing aid users: Using the International Outcome Inventory for Hearing Aids. Int J Audiol 2021; 61:119-129. [PMID: 34032544 DOI: 10.1080/14992027.2021.1916632] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
OBJECTIVE Primarily to understand whether clinically relevant factors affect the International Outcome Inventory (IOI-HA) scores and to examine if IOI-HA scores improve when renewing the hearing aids (HA) for experienced users. Secondly, to estimate the overall HA effectiveness using the IOI-HA. DESIGN A prospective observational study. STUDY SAMPLE In total, 1961 patients with hearing loss were included. All patients underwent a hearing examination, were fitted with HAs, and answered the IOI-HA. Factor analysis of IOI-HA separated the items into a Factor 1 (use of HA, perceived benefits, satisfaction, and quality of life) and Factor 2 (residual activity limitation, residual participation restriction and impact on others) score. RESULTS Degree of hearing loss, word recognition score, motivation, HA usage time, tinnitus, asymmetry, and sex were significantly associated with total IOI-HA, Factor 1, or Factor 2 scores. The seven IOI-HA items increased on average by 0.4 (p < 0.001) when renewing HAs. The total median IOI-HA score at follow-up was 29 (7) for experienced (n = 460) and first-time users (n = 1189), respectively. CONCLUSIONS Degree of hearing loss, word recognition score, motivation, tinnitus, asymmetry, and sex may be used to identify patients who require special attention to become successful HA users.
Collapse
Affiliation(s)
- S S Houmøller
- Research Unit for ORL - Head & Neck Surgery and Audiology, Odense University Hospital, Odense, Denmark.,Department of Clinical Research, Faculty of Health Science, University of Southern Denmark, Odense, Denmark.,OPEN, Odense Patient Data Explorative Network, Odense University Hospital, Odense, Denmark
| | - A Wolff
- Department of Otolaryngology, Head and Neck Surgery and Audiology, Aalborg University Hospital, Aalborg, Denmark
| | - S Möller
- Research Unit for ORL - Head & Neck Surgery and Audiology, Odense University Hospital, Odense, Denmark.,Department of Clinical Research, Faculty of Health Science, University of Southern Denmark, Odense, Denmark.,OPEN, Odense Patient Data Explorative Network, Odense University Hospital, Odense, Denmark
| | - V K Narne
- Research Unit for ORL - Head & Neck Surgery and Audiology, Odense University Hospital, Odense, Denmark
| | - S K Narayanan
- Department of Electronic Systems, Aalborg University, Aalborg, Denmark
| | - C Godballe
- Research Unit for ORL - Head & Neck Surgery and Audiology, Odense University Hospital, Odense, Denmark.,Department of Clinical Research, Faculty of Health Science, University of Southern Denmark, Odense, Denmark.,OPEN, Odense Patient Data Explorative Network, Odense University Hospital, Odense, Denmark
| | - D D Hougaard
- Department of Otolaryngology, Head and Neck Surgery and Audiology, Aalborg University Hospital, Aalborg, Denmark.,Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
| | - G Loquet
- Department of Otolaryngology, Head and Neck Surgery and Audiology, Aalborg University Hospital, Aalborg, Denmark.,Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
| | - M Gaihede
- Department of Otolaryngology, Head and Neck Surgery and Audiology, Aalborg University Hospital, Aalborg, Denmark.,Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
| | - D Hammershøi
- Department of Electronic Systems, Aalborg University, Aalborg, Denmark
| | - J H Schmidt
- Research Unit for ORL - Head & Neck Surgery and Audiology, Odense University Hospital, Odense, Denmark.,Department of Clinical Research, Faculty of Health Science, University of Southern Denmark, Odense, Denmark.,OPEN, Odense Patient Data Explorative Network, Odense University Hospital, Odense, Denmark
| |
Collapse
|
14
|
Miller K, Zhao F, Clark A, Wilkinson G, Laeufle R, Wolff A. Abstract OT-13-02: Bracelet-1 (pre0113): A study to assess overall response rate by inducing an inflammatory phenotype in metastatic breast cancer with the oncolytic reovirus pelareorep in combination with anti-PD-L1 avelumab and paclitaxel. Cancer Res 2021. [DOI: 10.1158/1538-7445.sabcs20-ot-13-02] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: A randomized phase 2 study with the intravenously delivered oncolytic virus, pelareorep, in combination with paclitaxel (PTX) demonstrated a statistically significant improvement in overall survival (OS) from 10.4 months with PTX alone to 17.4 months with pelareorep + PTX (HR 0.65, 80% CI 0.46-0.91, P = 0.1) in metastatic breast cancer (mBC) patients. The greatest benefit in OS was seen in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) disease (Bernstein et al, 2018). However, pelareorep + PTX did not improve progression-free survival or objective response relative to PTX alone, suggesting a late-onset adaptive immune response. A subsequent window of opportunity study in early breast cancer has shown that pelareorep can indeed promote an adaptive immune response in breast cancer tissue, enhancing CD8+ T cell infiltration and upregulating PD-L1 expression, correlating with high levels of viral replication in HR+/HER2- tumor tissue (Manso et al, 2020). Moreover, high levels of peripheral T cell clonality (PTCC) have been identified as a candidate blood-based on-treatment biomarker for pelareorep therapy, further highlighting the role of an adaptive immune response in driving pelareorep mediated efficacy (Mahalingam et al, 2020; Manso et al, 2020). Thus, BRACELET-1 will test the hypothesis that pelareorep mediated priming of an adaptive immune response will be synergistic with checkpoint blockade therapy in HR+/HER2- mBC. Moreover, BRACELET-1 will further assess PTCC as an on-treatment biomarker. The overall goal of this study is to expand the number of mBC patients who can benefit from better immunotherapy.
Study Design: This is an open-label randomized phase 2, three-cohort study in HR+/HER2- mBC. Patients must be refractory to endocrine therapy and have received prior treatment with a CDK4/6 inhibitor. Study cohorts include: Cohort 1, a control group receiving PTX (n = 15); Cohort 2, treatment with pelareorep added to PTX (n = 15); Cohort 3, treatment with pelareorep, PTX, and avelumab (n = 18). The study includes a three patient safety run-in for Cohort 3.
Specific aims: (1) Evaluation of efficacy in terms of overall response rate (ORR) at week 16, according to RECIST v1.1; (2) Examination of the safety of the study treatments; and (3) Assessment of key biomarkers, such as PTCC which will be correlated to treatment efficacy.
Present accrual and target accrual: The study is currently enrolling and is registered on clinicaltrials.gov: NCT04215146. Current enrollment = 2; Target enrollment = 48. This study is conducted through PrECOG, LLC and Oncolytics Biotech, Inc. Study contact information: PrE0113@precogllc.org.
Citation Format: Kathy Miller, Fengmin Zhao, Amy Clark, Grey Wilkinson, Rita Laeufle, Antonio Wolff. Bracelet-1 (pre0113): A study to assess overall response rate by inducing an inflammatory phenotype in metastatic breast cancer with the oncolytic reovirus pelareorep in combination with anti-PD-L1 avelumab and paclitaxel [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr OT-13-02.
Collapse
Affiliation(s)
| | | | - Amy Clark
- 3University of Pennsylvania, Philadelphia, PA
| | | | | | | |
Collapse
|
15
|
Johne R, Wolff A, Gadicherla AK, Filter M, Schlüter O. Stability of hepatitis E virus at high hydrostatic pressure processing. Int J Food Microbiol 2020; 339:109013. [PMID: 33340943 DOI: 10.1016/j.ijfoodmicro.2020.109013] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2020] [Revised: 12/01/2020] [Accepted: 12/02/2020] [Indexed: 01/26/2023]
Abstract
Hepatitis E virus (HEV) is the causative agent of acute and chronic hepatitis in humans. The zoonotic HEV genotype 3 is the main genotype in Europe. The foodborne transmission via consumption of meat and meat products prepared from infected pigs or wild boars is considered the major transmission route of this genotype. High hydrostatic pressure processing (HPP) is a technique, which can be used for inactivation of pathogens in food. Here, preparations of a cell culture-adapted HEV genotype 3 strain in phosphate-buffered saline (PBS) were subjected to HPP and the remaining infectivity was titrated in cell culture by counting fluorescent foci of replicating virus. A gradual decrease in infectivity was found by application of 100 to 600 MPa for 2 min. At 20 °C, infectivity reduction of 0.5 log10 at 200 MPa and 1 log10 at 400 MPa were observed. Slightly higher infectivity reduction of 1 log10 at 200 MPa and 2 log10 at 400 MPa were found by application of the pressure at 4 °C. At both temperatures, the virus was nearly completely inactivated (>3.5 log10 infectivity decrease) at 600 MPa; however, low amounts of remaining infectious virus were observed in one of three replicates in both cases. Transmission electron microscopy showed disassembled and distorted particles in the preparations treated with 600 MPa. Time-course experiments at 400 MPa showed a continuous decline of infectivity from 30 s to 10 min, leading to a 2 log10 infectivity decrease at 20 °C and to a 2.5 log10 infectivity decrease at 4 °C for a 10 min pressure application each. Predictive models for inactivation of HEV by HPP were generated on the basis of the generated data. The results show that HPP treatment can reduce HEV infectivity, which is mainly dependent on pressure height and duration of the HPP treatment. Compared to other viruses, HEV appears to be relatively stable against HPP and high pressure/long time combinations have to be applied for significant reduction of infectivity.
Collapse
Affiliation(s)
- R Johne
- German Federal Institute for Risk Assessment, Max-Dohrn-Straße 8-10, 10589 Berlin, Germany.
| | - A Wolff
- German Federal Institute for Risk Assessment, Max-Dohrn-Straße 8-10, 10589 Berlin, Germany
| | - A K Gadicherla
- German Federal Institute for Risk Assessment, Max-Dohrn-Straße 8-10, 10589 Berlin, Germany
| | - M Filter
- German Federal Institute for Risk Assessment, Max-Dohrn-Straße 8-10, 10589 Berlin, Germany
| | - O Schlüter
- Leibniz Institute for Agricultural Engineering and Bioeconomy, Quality and Safety of Food and Feed, Germany
| |
Collapse
|
16
|
Murthy R, O’Brien B, Berry D, Navin N, Johnson J, Gule-Monroe M, Leone J, Specht J, Melisko M, Morikawa A, Storniolo A, Brufsky A, Pohlmann P, Park D, Park B, Krop I, Lin N, Rimawi M, Wolff A, Forero-Torres A, Stringer-Reasor E. CTNI-02. TBCRC049: A PHASE II STUDY TO ASSESS THE SAFETY AND EFFICACY OF THE COMBINATION OF TUCATINIB, TRASTUZUMAB AND CAPECITABINE FOR THE TREATMENT OF LEPTOMENINGEAL METASTASIS IN HER2 POSITIVE BR1AST CANCER. Neuro Oncol 2020. [DOI: 10.1093/neuonc/noaa215.169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Treatment options for patients with leptomeningeal metastasis (LM) from HER2-positive breast cancer (HER2+ BC) are limited and prognosis is poor. Tucatinib is an oral, potent, HER2 specific tyrosine kinase inhibitor with good tolerability and combinatory anti-tumor activity, including partial responses in heavily treated patients and those with brain metastases (BM). This is a phase 2 single-arm study to evaluate the efficacy of tucatinib, trastuzumab and capecitabine in HER2+ BC with newly-diagnosed LM. CNS disease will be evaluated at screening and every 6 weeks by neuroaxis MRI, CSF cytology, and neurological assessments per RANO-LMD (adapted) and RANO-BM criteria. Extra-CNS disease will be evaluated at screening and every 12 weeks by CT scan per RECIST criteria. All patients will be followed for survival. Symptom burden and quality of life assessments, as well as correlative blood and CSF samples, will be collected. Eligible patients include adults with HER2+ BC, KPS > 50, and newly-diagnosed, untreated LM (defined as positive CSF cytology and/or radiographic evidence of LM, plus clinical signs/symptoms). Patients with treated or concurrent/new BM are allowed. Patients treated with capecitabine within the last 12 months are excluded. This study has a Gehan-like design with an interim futility analysis and overall intent to estimate OS. For the interim analysis, success is defined as CNS PFS for 12 weeks. Enrollment will end if fewer than two successes are observed in the first 15 patients. Secondary endpoints include safety, CNS PFS at 12 weeks, RR in CNS and extra-CNS, and symptom burden/quality of life. The regimen will be considered worthy of future study if the median OS is > 4.4 months. Fourteen of 30 patients have accrued thus far. The study is active at multiple Translational Breast Cancer Research Consortium sites around the country.
Collapse
Affiliation(s)
- Rashmi Murthy
- University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | | | - Donald Berry
- University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Nicholas Navin
- University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Jason Johnson
- University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | | | - Jose Leone
- Dana-Farber Cancer Institute, Boston, MA, USA
| | | | | | | | - Anna Storniolo
- The Melvin and Bren Simon Cancer Center at Indiana University, Indianapolis, IN, USA
| | | | | | | | - Ben Park
- Vanderbilt University Medical Center, Nashville, TN, USA
| | - Ian Krop
- University of Washington, Seattle, WA, USA
| | - Nancy Lin
- Dana-Farber Cancer Institute, Boston, MA, USA
| | - Mothaffar Rimawi
- Duncan Comprehensive Cancer Center at Baylor College of Medicine, Houston, TX, USA
| | | | | | - Erica Stringer-Reasor
- University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL, USA
| |
Collapse
|
17
|
Abbassi S, Wolff A. M551 EOSINOPHILIC CELLULITIS: A TREATMENT REFRACTORY CASE. Ann Allergy Asthma Immunol 2020. [DOI: 10.1016/j.anai.2020.08.378] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
18
|
Wolff A, Günther T, Albert T, Schilling-Loeffler K, Gadicherla AK, Johne R. Stability of hepatitis E virus at different pH values. Int J Food Microbiol 2020; 325:108625. [PMID: 32361052 DOI: 10.1016/j.ijfoodmicro.2020.108625] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2020] [Revised: 03/26/2020] [Accepted: 03/30/2020] [Indexed: 12/27/2022]
Abstract
Infection with the hepatitis E virus (HEV) can cause acute and chronic hepatitis in humans. The zoonotic HEV genotype 3 is mainly transmitted by consumption of raw and fermented meat products prepared from infected pigs or wild boars. Lowering of pH during fermentation is one of the microbiological hurdles considered to inhibit growth of certain pathogens. However, no data are currently available on pH stability of HEV. As a reliable and reproducible measurement of HEV infectivity in meat products is not established so far, the stability of the cell culture-adapted HEV genotype 3 strain 47832c was analyzed here in phosphate-buffered saline (PBS) at different pH values. Only a minimal decrease of infectivity (up to 0.6 log10 focus forming units) was found after treatment at pH 2 to 9 for 3 h at room temperature. At pH 10, a decrease of about 3 log10 was evident, whereas no remaining virus (>3.5 log10 decrease) was detected at pH 1. The conditions usually achieved during curing of raw sausages were simulated using D/L-lactic acid added to PBS resulting in pH 4.5 to 6.5. After incubation at 4 °C for 7 days at these conditions, no significant differences as compared to a standard PBS solution at pH 7.7 were evident. At room temperature, a 0.8 log10 decrease was found at pH 4.7 after 7 days incubation compared to pH 7.7, but less at the other pH values. In conclusion, only minimal inactivating effects were found at pH conditions commonly occurring during food processing. Therefore, remaining infectious virus might be present in fermented meat products if HEV-contaminated starting material was used. Additional effects of other factors like high salt concentrations and low aw values should be investigated in future studies.
Collapse
Affiliation(s)
- A Wolff
- German Federal Institute for Risk Assessment, Department of Biological Safety, Diedersdorfer Weg 1, 12277 Berlin, Germany
| | - T Günther
- German Federal Institute for Risk Assessment, Department of Biological Safety, Diedersdorfer Weg 1, 12277 Berlin, Germany
| | - T Albert
- University of Leipzig, Institute for Food Hygiene, An den Tierkliniken 1, 04103 Leipzig, Germany
| | - K Schilling-Loeffler
- German Federal Institute for Risk Assessment, Department of Biological Safety, Diedersdorfer Weg 1, 12277 Berlin, Germany
| | - A K Gadicherla
- German Federal Institute for Risk Assessment, Department of Biological Safety, Diedersdorfer Weg 1, 12277 Berlin, Germany
| | - R Johne
- German Federal Institute for Risk Assessment, Department of Biological Safety, Diedersdorfer Weg 1, 12277 Berlin, Germany.
| |
Collapse
|
19
|
Hunter N, Parsons H, Sherry A, Shinn D, Shin DH, Cole A, Cragnotti G, Groginski T, Leathers M, Richardson AL, Argani P, Wolff A, Cope L, Edelstein D, Holtrup F, Sloane H, Chakravarthy B, Stearns V, Park BH. Abstract P6-10-05: TBCRC 040: Pathologic response evaluation and detection in circulating tumor DNA (PREDICT DNA): Initial results piloting a tissue-biopsy independent method of identifying and monitoring tumor-specific mutations in early stage breast cancer. Cancer Res 2020. [DOI: 10.1158/1538-7445.sabcs19-p6-10-05] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: The PREDICT DNA trial is the first prospective, multi-center study aimed at validating cell-free plasma derived circulating tumor DNA (ctDNA) as a biomarker for treatment response and recurrence in early stage, triple-negative or HER2-positive (any hormone receptor status) breast cancer. Its primary aim is to determine the negative predictive value (NPV) of the absence of ctDNA after neoadjuvant therapy (NAT) for the achievement of pathologic complete response (pCR). This study has met its accrual goals and results of the overall trial are anticipated within the next year. The initial PREDICT DNA study design stipulated that tumor specific mutations (TSMs) to be tracked in blood would be identified by next gen sequencing (NGS) of tumor biopsy tissue. A disadvantage of this design is the dependence on adequate biopsy tissue. Recently, the advent of Safe-SeqS technology has enabled robust detection of rare variants using NGS with a sensitivity of approximately 0.05% mutant allele fraction. We employed these new NGS methods to pilot a novel tissue-independent approach to ctDNA detection and monitoring. Objective: The primary objective of this pilot study was to determine whether ultrasensitive NGS using a targeted cancer mutation panel can identify TSMs in ctDNA of early-stage breast cancer patients without the use of biopsy tissue. Methods: The PREDICT DNA trial enrolled 228 women from 22 sites with stage II/III breast cancer for whom standard neoadjuvant therapy was planned. Of these, 58 patients had matched pre-and post-NAT samples available for analysis at the time of this pilot. All pre-NAT samples were analyzed for the presence of TSMs using Sysmex Inostics’ SafeSEQ. Patients with detectable ctDNA before NAT were also evaluated for residual ctDNA after completion of NAT but prior to surgery. Five samples were also tested by digital PCR (BEAMing) for cross-platform comparison. Results: TSMs in ctDNA were identified in 29 of 58 patients (50%) prior to NAT. Of pre-NAT ctDNA(+) patients, TSMs were detected in TP53 (90%) and PIK3CA (10%); three patients (10%) were found to have 2 TSMs. Concordance between SafeSEQ and BEAMing was 100% in five samples tested [3 ctDNA(+), 2 ctDNA(-)]. Of 29 ctDNA(+) patients, 24 (83%) demonstrated reduction or elimination of detectable ctDNA following neoadjuvant therapy, with 16 (55%) converting to ctDNA(-). Conclusion: Identification of TSMs in the plasma of early-stage breast cancer patients without the need for biopsy tissue is feasible using a SafeSEQ cancer mutation panel. Further measures to improve the sensitivity of pre-treatment TSM analysis, such as increased plasma volume input and comprehensive TP53 mutational analysis are currently under investigation. Correlations between clinicopathologic factors with ctDNA detection and burden, as well as the NPV of post-NAT ctDNA for pCR and residual cancer burden, will be reported at the time of abstract presentation.
NH and HP contributed equally to this work.
Citation Format: Natasha Hunter, Heather Parsons, Alexander Sherry, Daniel Shinn, Dong Ho Shin, Alex Cole, Giovanni Cragnotti, Taylor Groginski, Margaret Leathers, Andrea L Richardson, Pedram Argani, Antonio Wolff, Leslie Cope, Dan Edelstein, Frank Holtrup, Hilary Sloane, Bapsi Chakravarthy, Vered Stearns, Ben H Park. TBCRC 040: Pathologic response evaluation and detection in circulating tumor DNA (PREDICT DNA): Initial results piloting a tissue-biopsy independent method of identifying and monitoring tumor-specific mutations in early stage breast cancer [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P6-10-05.
Collapse
Affiliation(s)
| | | | | | | | - Dong Ho Shin
- 3Vanderbilt University Medical Center, Nashville, TN
| | - Alex Cole
- 4Johns Hopkins University, Baltimore, MD
| | | | | | | | | | | | | | | | | | | | | | | | | | - Ben H Park
- 3Vanderbilt University Medical Center, Nashville, TN
| |
Collapse
|
20
|
Murthy RK, O'Brien BJ, Hess KR, Navin N, Johnson J, Gule-Monroe M, Leone JP, Specht J, Melisko M, Morikawa A, Storniolo AM, Brufsky A, Pohlmann PR, Park DM, Park BH, Krop I, Lin NU, Wolff A, Forerro-Torres A, Stringer-Reasor E. Abstract OT2-01-02: TBCRC049: A phase II non-randomized study to assess the safety and efficacy of the combination of tucatinib and trastuzumab and capecitabine for treatment of leptomeningeal metastases in HER2 positive breast cancer TBCRC049: A phase II non-randomized study to assess the safety and efficacy of the combination of tucatinib and trastuzumab and capecitabine for treatment of leptomeningeal metastases in HER2 positive breast cancer. Cancer Res 2020. [DOI: 10.1158/1538-7445.sabcs19-ot2-01-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Treatment options for patients with leptomeningeal disease (LMD) from HER2-positive breast cancer (HER2+ BC) are limited, and the prognosis is poor. Tucatinib is an oral, potent, HER2 specific tyrosine kinase inhibitor with good tolerability and notable early combinatory anti-tumor activity, including partial responses in heavily treated patients and those with parenchymal brain metastases (BM). Trial Design: This is a phase 2 single arm study to evaluate the efficacy of the combination of tucatinib plus trastuzumab (T) and capecitabine(C) in patients with HER2+ BC and newly diagnosed LMD. CNS disease will be evaluated at screening and every six weeks by MRI, CSF cytology, and neurological assessments according to RANO-LMD (adapted) and RANO-BM criteria. CT scans/PET-CT will evaluate extracranial disease according to RECIST criteria at screening and every 12 weeks. All patients will be followed for survival from the date of the last dose until death, lost to follow-up, or consent withdrawal. Symptom burden and quality of life assessments are conducted throughout the study. Blood and CSF sample collections occur at each cycle for the planned correlative analyses. Eligibility Criteria: Eligible patients are adults (>18 years old) with HER2+ BC, ECOG status<3/KPS>50, and newly diagnosed untreated LMD (defined as positive CSF cytology and/or radiographic evidence of LMD, plus clinical signs/symptoms. Patients with a history of treated BM or concurrent/new BM are allowed. Patients previously treated with tucatinib or capecitabine (within the last 12 months) are excluded. Specific Aims: The primary endpoint is OS. Secondary endpoints include safety, CNS PFS at 12 weeks, RR and CBR in CNS and extra-CNS disease, and symptom burden/quality of life. Statistical methods: This study has a Gehan-like design with an interim futility analysis and overall intent to estimate OS. For the interim analysis, we define success to be CNS PFS for 12 weeks. An event will be considered to be either CNS progression or death from any cause before 12 weeks.We will stop enrollment if there are fewer than two successes in the first 15 patients. If the trial continues to completion, the regimen will be considered worthy of future study if the median overall survival is > 4.4 months. Study Accrual: The target accrual is 30 patients. The study is currently active at UAB and MDACC. Other TBCRC sites throughout the country are to be activated this year.
Citation Format: Rashmi K Murthy, Barbara J O'Brien, Ken R Hess, Nick Navin, Jason Johnson, Maria Gule-Monroe, Jose P Leone, Jennifer Specht, Michelle Melisko, Aki Morikawa, Anna M Storniolo, Adam Brufsky, Paula R Pohlmann, Deric M Park, Ben H Park, Ian Krop, Nancy U Lin, Antonio Wolff, Andres Forerro-Torres, Erica Stringer-Reasor. TBCRC049: A phase II non-randomized study to assess the safety and efficacy of the combination of tucatinib and trastuzumab and capecitabine for treatment of leptomeningeal metastases in HER2 positive breast cancer TBCRC049: A phase II non-randomized study to assess the safety and efficacy of the combination of tucatinib and trastuzumab and capecitabine for treatment of leptomeningeal metastases in HER2 positive breast cancer [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr OT2-01-02.
Collapse
Affiliation(s)
| | | | - Ken R Hess
- 1University of Texas MD Anderson Cancer Center, Houston, TX
| | - Nick Navin
- 1University of Texas MD Anderson Cancer Center, Houston, TX
| | - Jason Johnson
- 1University of Texas MD Anderson Cancer Center, Houston, TX
| | | | | | | | | | | | - Anna M Storniolo
- 6The Melvin and Bren Simon Cancer Center at Indiana University, Indianapolis, IN
| | | | - Paula R Pohlmann
- 8Georgetown Lombardi Comprehensive Cancer Center, Washington D.C., DC
| | | | | | - Ian Krop
- 2Dana-Farber Cancer Institute, Boston, MA
| | | | | | | | - Erica Stringer-Reasor
- 13University of Alabama at Birmingham O’Neal Comprehensive Cancer Center, Birmingham, AL
| |
Collapse
|
21
|
Partridge A, Zheng Y, Rosenberg S, Gelber R, Gelber S, Barry W, Dang C, Yardley D, Isakoff S, Valero V, Faggen M, Mulvey T, Bose R, Weckstein D, Wolff A, Reeder-Hayes K, Rugo H, Ramaswamy B, Zuckerman D, Hart L, Gadi V, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett M, Marcom PK, Albain K, Defusco P, Tung N, Ardman B, Nanda R, Jankowitz R, DeMeo M, Burstein H, Winer EP, Krop I, Tolaney S. Abstract PD10-02: Patient reported outcomes from the adjuvant trastuzumab emtansine (T-DM1) vs. paclitaxel + trastuzumab (TH) (ATEMPT) trial (TBCRC 033). Cancer Res 2020. [DOI: 10.1158/1538-7445.sabcs19-pd10-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose: The ATEMPT trial sought to determine if adjuvant T-DM1 (every 3 wks for 1 yr) for Stage I HER2 positive breast cancer is better tolerated than TH (paclitaxel weekly x 12 wks with 1 yr of trastuzumab). Here we compare patient-reported outcomes (PROs) including quality of life (QOL), specific symptoms, and work productivity between the two treatments over time. Patients and Methods: English-speaking patients were randomized (3:1) to T-DM1 or TH, and completed PRO assessments at baseline (day 1), 3 wks, 12 wks, and 6, 12, and 18 mos after initiation of treatment. Surveys included the FACT-B, Patient-Neurotoxicity Questionnaire (PNQ), Rotterdam Symptom Checklist (RSCL), Alopecia Patient Assessment, and Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP). Results: 469/497 (94%) patients (363 on T-DM1, 106 on TH) completed surveys at any timepoint, ranging from 100% at baseline to 79% at 18 mos. Median age was 56 yrs (range 23-85). There were different patterns of deterioration and recovery seen over time in each group for QOL and other relevant symptoms. Compared with the T-DM1 group, the TH group had significantly lower mean total FACT-B scores, indicating poorer QOL from baseline to 12 weeks (p<0.001 for each timepoint); mean scores were similar between the groups at 6 and 12 mos, and significantly worse again in the TH group at 18 mos. The greatest mean change from baseline, and lowest FACT-B scores overall were reported in the TH group at 12 weeks. Moderate to severe sensory neuropathy was 8% at 12 weeks for patients receiving T-DM1 and reached its highest level of 15% by 18 mos. In comparison, moderate to severe sensory neuropathy was 35% at 12 weeks and 26% at 18 mos for patients on TH (p<0.001 at 12 weeks and p=0.018 at 18 mos). Hair loss at week 12 was 13% on T-DM1 compared to 77% on TH (p<0.001). Mean physical symptom distress was greater for TH at baseline, 3 and 12 weeks, and greater for T-DM1 at 1 year, with greatest symptom distress reported by the TH group at 12 weeks. Psychological distress was greatest for both groups at enrollment, though significantly greater with TH than T-DM1 at baseline, 12 weeks and 18 mos (groups were similar at 6 and 12 mos). There was limited impact on activity level impairment in both groups. Rates of employment were lowest for the TH group at 12 weeks (49% TH vs. 61% T-DM1, p=0.074) with significant differences seen at 3 and 12 weeks for percent work time missed due to health treatment, percent impairment while working, percent overall work impairment, and percent activity impairment, all favoring T-DM1. Conclusion: PROs differ between patients with Stage I HER2 positive breast cancer treated with T-DM1 vs. TH. T-DM1 treated patients had better QOL, less neuropathy and hair loss, and better work productivity, particularly during the first 12 weeks of treatment, and importantly, differences persist with longer-term follow-up.
Citation Format: Ann Partridge, Yue Zheng, Shoshana Rosenberg, Richard Gelber, Shari Gelber, William Barry, Chau Dang, Denise Yardley, Steven Isakoff, Vicente Valero, Meredith Faggen, Therese Mulvey, Ron Bose, Douglas Weckstein, Antonio Wolff, Katherine Reeder-Hayes, Hope Rugo, Bhuvaneswari Ramaswamy, Dan Zuckerman, Lowell Hart, Vijayakrishna Gadi, Michael Constantine, Kit Cheng, Frederick Briccetti, Bryan Schneider, Merrill Garrett, P. Kelly Marcom, Kathy Albain, Patricia Defusco, Nadine Tung, Blair Ardman, Rita Nanda, Rachel Jankowitz, Michelle DeMeo, Harold Burstein, Eric P. Winer, Ian Krop, Sara Tolaney. Patient reported outcomes from the adjuvant trastuzumab emtansine (T-DM1) vs. paclitaxel + trastuzumab (TH) (ATEMPT) trial (TBCRC 033) [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr PD10-02.
Collapse
Affiliation(s)
| | - Yue Zheng
- 1Dana-Farber Cancer Institute, Boston, MA
| | | | | | | | | | - Chau Dang
- 2Memorial Sloan Kettering Cancer Center, New York, NY
| | | | | | | | | | | | - Ron Bose
- 6Washington University School of Medicine, St. Louis, MO
| | | | | | | | - Hope Rugo
- 9Helen Diller Comprehensive Cancer Center, University of California, San Francisco, CA
| | | | - Dan Zuckerman
- 11St. Luke's Mountain States Tumor Institute, Boise, ID
| | - Lowell Hart
- 12Florida Cancer Specialists and Wake Forest School of Medicine, Ft. Meyers, FL
| | | | | | - Kit Cheng
- 13Northwell Health, Lake Success, NY
| | | | - Bryan Schneider
- 14Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
| | | | | | - Kathy Albain
- 17Loyola University Stritch School of Medicine, Chicago, IL
| | | | - Nadine Tung
- 19Beth Israel Deaconess Medical Center, Boston, MA
| | | | | | | | | | | | | | - Ian Krop
- 1Dana-Farber Cancer Institute, Boston, MA
| | | |
Collapse
|
22
|
Xie EG, Lapinski MM, Talamantes S, Visvanathan K, Wolff A, Santa-Maria C. Abstract P5-04-16: Association of circulating immune cells with lifestyle factors, and recurrence and mortality in patients with early stage breast cancer. Cancer Res 2020. [DOI: 10.1158/1538-7445.sabcs19-p5-04-16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Lifestyle factors and metabolic derangements have wide-ranging effects including on immune activity. The association of circulating immune cells and outcomes in patients with early stage breast cancer remain incompletely understood.
Objective: To evaluate the effects of smoking, body mass index (BMI), and alcohol intake on the association between circulating immune cell levels and patient outcomes.
Methods: We retrospectively screened the electronic medical record of 950 patients with early stage breast cancer at the Johns Hopkins Hospital between 2003-2008 with at least 5 years of follow-up data for information on complete blood cell (CBC) counts. Absolute lymphocyte, monocyte, and neutrophil counts were obtained from the CBC differential performed closest to time of diagnosis within a period of ±1 year, and prior to any systemic treatment. Statistical analyses used were t-test for comparison of recurrence vs non-recurrence and Cox proportional hazard models for survival analysis, and linear regression for association between counts and BMI. Covariates adjusted for include grade, stage, smoking status, and alcohol use.
Results: A total of 433 patients with stage 0-III breast cancer had complete data and were included in the analytical population. The populations of analyzed and non-analyzed patients were not significantly different in age or ethnic composition. The median age was 53 years old (range 26-86); 24% (n=103) were African American, and 76% (n=330) were Caucasian. Median BMI at baseline was 27 (range 18-53). Breast cancer subtypes were 68% (n=293) hormone receptor-positive, 19% (n=82) HER2 positive, and 13% (n=53) triple negative. 7.6% (n=33) experienced a recurrence and 6.9% (n=30) died of all causes. Patients with the highest quartile of lymphocytes at diagnosis, compared to the lowest quartile, had a significantly lower risk of recurrence (HR=0.23, 95% CI [0.06, 0.87], p=0.031). Patients with the highest quartile of monocytes were also at a lower risk for recurrence (HR= 0.17, 95% CI [0.11, 0.72] p=0.02). This effect was magnified in subgroup analysis among patients with hormone negative (n=125, p=0.017) and grade 3 (n=155, p=0.02) breast cancer. Patients in the highest quartile of both lymphocytes and monocytes had similarly lower recurrence rates (HR=0.24, 95% CI [0.08, 0.88] p=0.034). In subgroup analysis with regard to lifestyle factors, association of higher monocytes with lower recurrence was most significant among those consuming alcohol (n=237, p=0.005). Subgroup analysis of alcohol use was unremarkable for lymphocytes, as was subgroup analysis of smoking history (n=144) for lymphocytes and monocytes. In patients with BMI>30, lower lymphocytes were more strongly associated with recurrence (n=144, p=0.04); conversely, in patients with BMI<30, lower monocytes were more strongly associated with recurrence (n=289, p=0.02). There was no association between BMI and either monocytes or lymphocytes.
Conclusion: Higher recurrence rates are observed in patients with early stage breast cancer who have low-normal lymphocyte and monocyte counts at time of diagnosis. This association is stronger in subgroups of patient with high BMI and who consume alcohol, known risk factors for breast cancer.
Citation Format: Eric G Xie, Maya M Lapinski, Sarah Talamantes, Kala Visvanathan, Antonio Wolff, Cesar Santa-Maria. Association of circulating immune cells with lifestyle factors, and recurrence and mortality in patients with early stage breast cancer [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P5-04-16.
Collapse
Affiliation(s)
- Eric G Xie
- Johns Hopkins University School of Medicine, Baltimore, MD
| | | | | | | | - Antonio Wolff
- Johns Hopkins University School of Medicine, Baltimore, MD
| | | |
Collapse
|
23
|
Gosseries O, Fecchio M, Wolff A, Sanz LRD, Sombrun C, Vanhaudenhuyse A, Laureys S. Behavioural and brain responses in cognitive trance: A TMS-EEG case study. Clin Neurophysiol 2019; 131:586-588. [PMID: 31843502 DOI: 10.1016/j.clinph.2019.11.011] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2019] [Accepted: 11/16/2019] [Indexed: 11/27/2022]
Affiliation(s)
- O Gosseries
- Coma Science Group, GIGA Consciousness, University and University Hospital of Liège, Liège, Belgium.
| | - M Fecchio
- Department of Biomedical and Clinical Sciences "L. Sacco", University of Milan, Milan, Italy
| | - A Wolff
- Coma Science Group, GIGA Consciousness, University and University Hospital of Liège, Liège, Belgium
| | - L R D Sanz
- Coma Science Group, GIGA Consciousness, University and University Hospital of Liège, Liège, Belgium
| | - C Sombrun
- TranceScience Research Institute, Paris, France
| | - A Vanhaudenhuyse
- Algology Department & Sensation & Perception Research Group, GIGA consciousness, University and University Hospital of Liège, Liège, Belgium
| | - S Laureys
- Coma Science Group, GIGA Consciousness, University and University Hospital of Liège, Liège, Belgium
| |
Collapse
|
24
|
Zellars R, Shah A, Young M, Wright J, de Souza Lawrence L, Stearns V, Wolff A. Outcomes from Two Phase I/II Trials of Partial-Breast Irradiation (PBI) and Concurrent Chemotherapy. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.703] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
25
|
Rugo HS, Mayer E, Storniolo AM, Isaacs C, Mayer I, Stearns V, Nanda R, Nangia J, Melisko M, Wabl C, Muzikansky A, Kochupurakkal B, Park BH, Wolff A, Shapiro G. Abstract CT128: Palbociclib in combination with fulvestrant or tamoxifen as treatment for hormone receptor positive metastatic breast cancer with prior chemotherapy for advanced disease (TBCRC 035): A Phase II study with pharmacodynamic markers. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-ct128] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Addition of the cyclin dependent kinase 4/6 inhibitor (CDK4/6i) palbociclib to endocrine therapy significantly improves progression free survival (PFS) in patients with HR+ MBC. The primary toxicity is neutropenia (ntp). TBCRC035 explored rates of neutropenia in patients with prior chemotherapy for MBC with 2 dose levels of palbociclib, and correlated changes in retinoblastoma protein phosphorylation (pRB) and Ki67 expression in proliferating keratinocytes and tumor, as well as mutations in cell-free DNA (cfDNA) with response.
Methods: TBCRC035 is a 1:1 randomized multicenter Phase II study evaluating palbociclib at either 125 or 100 mg in combination with physician choice fulvestrant or tamoxifen. Eligible patients (pts) with HR+ MBC had received 1-3 lines of chemotherapy for MBC, any number of hormone therapies, and were naïve to CDK4/6i. The primary endpoint was grade 3/4 ntp; secondary endpoints included PFS, clinical benefit rate (CBR), safety/tolerability, inhibition of RB phosphorylation (pRB) and change in Ki67 expression in skin and tumor (FFPE sections of skin and tumor biopsies) at day 14-21 of treatment compared to baseline, and correlation of response with mutations in cell free DNA (cfDNA). FFPE sections of skin punch and tumor biopsies were stained using antibodies to Ki67, total RB, and phospho-RB-S780 using BOND polymer red detection. Stained slides were scanned into the Aperio image analysis platform; the percentage of marker positive cells was determined. Whole blood was collected at baseline & processed for plasma; cfDNA was extracted. Using a combination of digital PCR and ultradeep next generation sequencing, cfDNA was analyzed for ESR1 and PIK3CA mutations.
Results: 70 pts were enrolled; 35 were randomized to 100 vs 125 mg of palbociclib respectively. 12 pts (100 mg), and 19 pts (125 mg) had >1 episode of grade 3/4 ntp (p=0.091). Pts on 100 mg had fewer total episodes of grade 3/4 ntp (p=0.036). Dose reductions were more frequent in patients starting with 125 mg compared to those starting with 100 mg (12 vs6). CBR and PFS were similar (100 vs 125 mg; CBR: 67 vs 74%; PFS: 6.5 vs 10 mo,p=0.18). In skin and tumor, the % of Ki67-positive nuclei was significantly lower in post-treatment biopsies (p<0.0001 for both) and was similarly reduced for pRb in skin, (tumor data pending); there was no significant difference in % change in pRB and Ki67 by palbociclib dose, or by CBR or PFS. Higher baseline tumor Ki67 was associated with worse PFS (p=0.006), regardless of dose. Presence of PIK3CA mutations in cfDNA correlated with worse PFS (p=0.008), but ESR1 mutations did not.
Conclusion: In pts with prior chemotherapy for HR+ MBC, treatment with 100 mg of palbociclib significantly reduced episodes of ntp and dose reductions; efficacy was comparable to patients treated with 125mg. Reductions in expression of Ki67 in tumor and keratinocytes and pRB in keratinocytes were comparable between dose levels indicating robust inhibition of CDK4/6 at both doses. The presence of PIK3CA mutations correlated with reduced PFS. These data suggest that dose reduction of palbociclib to mitigate toxicity should not compromise efficacy and provide additional prognostic information for use in treatment selection.
Citation Format: Hope S. Rugo, Erica Mayer, Anna Maria Storniolo, Claudine Isaacs, Ingrid Mayer, Vered Stearns, Rita Nanda, Julie Nangia, Michelle Melisko, Chiara Wabl, Alona Muzikansky, Bose Kochupurakkal, Ben H. Park, Antonio Wolff, Geoffrey Shapiro. Palbociclib in combination with fulvestrant or tamoxifen as treatment for hormone receptor positive metastatic breast cancer with prior chemotherapy for advanced disease (TBCRC 035): A Phase II study with pharmacodynamic markers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr CT128.
Collapse
Affiliation(s)
- Hope S. Rugo
- 1University of California San Francisco Comprehensive Cancer Center, San Francisco, CA
| | - Erica Mayer
- 2Dana Farber Comprehensive Cancer Center, Boston, MA
| | | | | | | | | | | | | | - Michelle Melisko
- 1University of California San Francisco Comprehensive Cancer Center, San Francisco, CA
| | - Chiara Wabl
- 1University of California San Francisco Comprehensive Cancer Center, San Francisco, CA
| | | | | | | | | | | |
Collapse
|
26
|
Schräder N, Duipmans J, Molenbuur B, Wolff A, Jonkman M. THC 联合 CBD 治疗 EB 疼痛. Br J Dermatol 2019. [DOI: 10.1111/bjd.17678] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
27
|
|
28
|
Wolff A, Joshi RK, Ekström J, Aframian D, Pedersen AML, Proctor G, Narayana N, Villa A, Sia YW, Aliko A, McGowan R, Kerr R, Jensen SB, Vissink A, Dawes C. [Medicaments and oral healthcare. Systematic review of the -literature assessing the effect of drugs on the salivary glands]. Ned Tijdschr Tandheelkd 2018; 125:593-601. [PMID: 30457580 DOI: 10.5177/ntvt.2018.11.18203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Evidence-based reviews of drugs causing medication-induced salivary gland dysfunction, such as xerostomia (sensation of oral dryness) and subjective sialorrhea are lacking. To compile a list of medicaments that influence salivary gland function, electronic databases were searched for relevant articles published up to June 2013. A total of 269 papers out of 3,867 records located satisfied the inclusion criteria (relevance, quality of methodology, strength of evidence). A total of 56 active substances with a higher level of evidence and 50 active substances with a moderate level of evidence of causing salivary gland dysfunction are described in this article. While xerostomia was a commonly reported outcome, the objective effect on salivary secretion was rarely measured. Xerostomia was, moreover, mostly reported as a negative side effect instead of the intended effect of that drug. A comprehensive list of medications having documented effects on salivary gland function or symptoms was compiled, which may assist practitioners in assessing patients who complain of dry mouth while taking medications.
Collapse
|
29
|
Ugalde A, Aranda S, Paul C, Orellana L, Plueckhahn I, Segan C, Baird D, Otmar R, Brown S, Armstrong P, Wolff A, Shee AW, Livingston P. Improving Health Outcomes for People With Cancer in Rural and Regional Areas by Embedding Evidence-Based Smoking-Cessation Strategies Into Usual Care: A Study Protocol. J Glob Oncol 2018. [DOI: 10.1200/jgo.18.10100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Background: Smoking following a diagnosis of cancer is a powerful clinical risk indicator, with known poorer health outcomes and associated health care costs. In Australia, smoking rates are higher in rural and regional areas. There are established and effective interventions to promote smoking cessation after a diagnosis of cancer yet these are not in routine practice. Aim: This protocol paper reports on a study that aims to embed evidence-based smoking cessation strategies for people with cancer who are current smokers into routine care, resulting in in system wide improvements, an implemented program and model for further dissemination. Methods: Across three rural/regional sites, and with partners Quit Victoria and Western Alliance, this study employs a variety of methodologies to embed smoking cessation support to improve outcomes for people with cancer who currently smoke. Specifically, the project will embed a system of responsibilities and training in rural and regional health services to routinely engage people with cancer who smoke in support services. The program will: · Promote routine delivery of smoking cessation care by trained oncology staff (oncologists/nurses/ allied health) · Establish referral pathways to Quitline · Correspond with general practitioners, to: i) outline the benefits of quitting in this context, ii) promote access to nicotine replacement therapy and iii) support quitting in the community. · Improve routine recording of smoking status and documentation of provision of brief intervention (personalised advice given, resources provided) and outcomes. Participants: are oncology staff and general practitioners across three health services: Ballarat Health Service, East Grampians Health Service (Ararat), Wimmera Health Care Group (Horsham), all located in Victoria, Australia. Data collection will occur across four sources: 1) Oncology staff: qualitative and quantitative data collection understanding confidence and views on provision on cessation advice; 2) Monitoring Quitline calls, 3) Interview with local general practitioners and 4) Medical record reviews to explore frequency of recording of smoking status. Data will be collected pre/postintervention. Results: The project is underway with the intervention manuals in development. The project is due for completion in 2020. Conclusion: This project takes a health services approach to integration of smoking cessation support in routine care for people with cancer in rural and regional areas. This program of work has capacity to determine best approaches to integrate smoking cessation into routine care, resulting in reduced mortality and morbidity, improved effectiveness of anticancer treatments, and reduced health care costs; by establishing internationally relevant, embedded health care interventions.
Collapse
Affiliation(s)
- A. Ugalde
- Deakin University, Melbourne, Australia
| | - S. Aranda
- Deakin University, Melbourne, Australia
| | - C. Paul
- Deakin University, Melbourne, Australia
| | | | | | - C. Segan
- Deakin University, Melbourne, Australia
| | - D. Baird
- Deakin University, Melbourne, Australia
| | - R. Otmar
- Deakin University, Melbourne, Australia
| | - S. Brown
- Deakin University, Melbourne, Australia
| | | | - A. Wolff
- Deakin University, Melbourne, Australia
| | | | | |
Collapse
|
30
|
Wolff A, Koray M, Campisi G, Strietzel FP, Lafaurie GI, Beiski BZ, Ekström J. Electrostimulation of the lingual nerve by an intraoral device may lead to salivary gland regeneration: A case series study. Med Oral Patol Oral Cir Bucal 2018; 23:e552-e559. [PMID: 30148471 PMCID: PMC6167107 DOI: 10.4317/medoral.22597] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2018] [Accepted: 06/30/2018] [Indexed: 11/18/2022] Open
Abstract
Background Salivary gland function is controlled by the salivary reflex, whose efferent arm is composed by the parasympathetic and the sympathetic divisions of the autonomic nervous system. Parenchymal injury is the main salivary gland involvement of Sjögren’s syndrome and head and neck radiotherapy, but neural damage has been reported as well. Recently an intraoral device for electrostimulation of the lingual nerve in vicinity to the lower third molar has been introduced. At this point this nerve carries efferent fibers for the innervation of the submandibular, sublingual and several minor salivary glands and afferent fibers of the salivary reflex. Therefore, excitation of these fibers potentially leads to increased secretion of all salivary glands. Thus, the study objective was to assess whether comprehensive neural activation by electrostimulation of the lingual nerve carries the potential to induce the regeneration of damaged salivary glands. Material and Methods The device was tested on three patients with no collectable resting and stimulated secretion of saliva during a double blind, sham controlled period of two months and nine open-label months. Results All three subjects developed the capacity to spit saliva, not only in direct response to the electrostimulation but also after free intervals without electrostimulation. In addition, their symptoms of dry mouth severity and frequency improved. Conclusions This recovery is probably due to the combined effect of increase in secretory functional gland mass and regain of nervous control of the secretory elements and blood vessels. Both are phenomena that would contribute to gland regeneration. Key words:Xerostomia, dry mouth, saliva, electrostimulation, regeneration.
Collapse
Affiliation(s)
- A Wolff
- 65 Hatamar St., Harutzim 60917, Israel,
| | | | | | | | | | | | | |
Collapse
|
31
|
Wolff A, Klingner N, Thompson W, Zhou Y, Lin J, Peng YY, Ramshaw JAM, Xiao Y. Modelling of focused ion beam induced increases in sample temperature: a case study of heat damage in biological samples. J Microsc 2018; 272:47-59. [PMID: 30019759 DOI: 10.1111/jmi.12731] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2017] [Revised: 06/08/2018] [Accepted: 06/13/2018] [Indexed: 11/27/2022]
Abstract
Ion beam induced heat damage in soft materials and biological samples is not yet well understood in Focused Ion Beam systems (FIBs). The work presented here discusses the physics behind the ion beam - sample interactions and the effects which lead to increases in sample temperature and potential heat damage. A model by which heat damage can be estimated and which allows parameters to be determined that reduce/prevent heat damage was derived from Fourier's law of heat transfer and compared to finite element simulations, numerical modelling results and experiments. The results suggests that ion beam induced heat damage can be prevented/minimised by reducing the ion beam current (local dose rate), decreasing the beam overlap (reduced local ion dose) and by introducing a blur (increased surface cross-section area, reduced local dose) while sputtering, patterning or imaging soft material and nonresin-embedded biological samples using FIBs. LAY DESCRIPTION FIB/SEMs, which combine a scanning electron microscope with a focused ion beam in a single device, have found increasing interest biological research. The device allows to cut samples at precisely selected areas and reveal sub surface information as well as preparing transmission electron microscope samples from bulk materials. Preparing biological samples has proven to be challenging due to the induced heat damage. This work explores the physics behind the sample cutting and proposes a model and a method, based on physical principles which allows the user to estimate the induced heat during the cutting process and to select cutting parameters which avoid heat damage in the sample.
Collapse
Affiliation(s)
- A Wolff
- Central Analytical Research Facility, Institute for Future Environments, Queensland University of Technology (QUT), Brisbane, Queensland, Australia
| | - N Klingner
- Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany
| | - W Thompson
- Heelionics LLC, Los Altos, California, U.S.A
| | - Y Zhou
- Institute of Health and Biomedical Innovation, Queensland University of Technology (QUT), Brisbane, Queensland, Australia.,The Australia-China Centre for Tissue Engineering and Regenerative Medicine (ACCTERM), Queensland University of Technology, Brisbane, Queensland, Australia
| | - J Lin
- Department of Implantology, Affiliated Stomatological Hospital of Xiamen Medical College, Fujan, China.,The Australia-China Centre for Tissue Engineering and Regenerative Medicine (ACCTERM), Queensland University of Technology, Brisbane, Queensland, Australia
| | - Y Y Peng
- CSIRO Manufacturing, Bayview Avenue, Clayton, Victoria, Australia
| | - J A M Ramshaw
- CSIRO Manufacturing, Bayview Avenue, Clayton, Victoria, Australia.,Department of Surgery, St. Vincent's Hospital, University of Melbourne, Victoria, Australia
| | - Y Xiao
- Institute of Health and Biomedical Innovation, Queensland University of Technology (QUT), Brisbane, Queensland, Australia.,The Australia-China Centre for Tissue Engineering and Regenerative Medicine (ACCTERM), Queensland University of Technology, Brisbane, Queensland, Australia
| |
Collapse
|
32
|
Vidula N, Goga A, Krummel M, Hwang J, Liu M, Park BH, Nanda R, Pohlmann P, Storniolo AM, Van Poznak C, Brufsky A, Abramson V, Wolff A, Rugo HS. Abstract OT1-02-03: TBCRC 044: A randomized phase II study of pembrolizumab in combination with carboplatin versus carboplatin alone in breast cancer patients with chest wall disease. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-ot1-02-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Patients with breast cancer (BC) and chest wall disease have limited treatment options. We hypothesize that checkpoint inhibition may be an effective treatment approach due to the inflammatory nature of chest wall infiltration, and the association of PD-1 expression with lymphocytic infiltration. Platinum chemotherapy may facilitate anti-tumor immunity in a synergistic manner, and clinical studies of the PD-1 inhibitor pembrolizumab with platinum combinations have been effective in the treatment of advanced lung cancer. In this study, we will evaluate the combination of carboplatin and pembrolizumab in BC patients with chest wall disease.
Methods: This is a randomized phase II multicenter study in the TBCRC including patients with advanced, unresectable BC with hormone resistant or triple negative chest wall disease. Patients may have had prior surgery, prior chest wall radiation is not required, and other sites of distant metastases are allowed. Eighty-four patients at TBCRC sites will be randomized 2:1 to receive pembrolizumab and carboplatin (n=56, Arm A) or carboplatin alone (n=28, Arm B) until disease progression. Patients randomized to Arm B may cross-over following progression to pembrolizumab alone (Arm Bx). Patients in Arm A will be treated with pembrolizumab 200 mg IV and carboplatin AUC 5 IV every 3 weeks for at least 6 cycles followed by maintenance pembrolizumab 200 mg IV every 3 weeks if stable or responding disease. Patients in Arm B will be treated with carboplatin AUC 5 IV every 3 weeks until progression, then may cross-over to pembrolizumab 200 mg IV every 3 weeks alone (Arm Bx). An interim analysis for futility will be performed after 18 patients are enrolled into Arm B to allow early closure of that arm for lack of efficacy. The primary endpoint is disease control rate at 18 weeks of treatment; the study is powered to detect a 20% difference in disease control rates between arms (hazard ratio 0.52, α= 0.10, β= 0.20). Secondary endpoints include progression free survival, toxicity, and response based on PD-L1 expression and irRECIST. Exploratory endpoints include association of response with a number of biomarkers including tumor PD-L1 gene expression, tumor and peripheral blood immune composition and cytokine expression, peripheral T-cell PD-1 expression, circulating tumor DNA, circulating tumor cells, and tumor MYC genomic expression using tumor biopsy and peripheral blood testing before and after treatment. This study should be open to accrual by August of 2017. (NCT03095352)
Citation Format: Vidula N, Goga A, Krummel M, Hwang J, Liu M, Park BH, Nanda R, Pohlmann P, Storniolo AM, Van Poznak C, Brufsky A, Abramson V, Wolff A, Rugo HS. TBCRC 044: A randomized phase II study of pembrolizumab in combination with carboplatin versus carboplatin alone in breast cancer patients with chest wall disease [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr OT1-02-03.
Collapse
Affiliation(s)
- N Vidula
- Massachussets General Hospital; University of California San Francisco Comprehensive Cancer Center; Mayo Clinic, Rochester; Johns Hopkins University; University of Chicago; Georgetown; University of Indiana; University of Michigan; University of Pittsburgh; Vanderbilt University
| | - A Goga
- Massachussets General Hospital; University of California San Francisco Comprehensive Cancer Center; Mayo Clinic, Rochester; Johns Hopkins University; University of Chicago; Georgetown; University of Indiana; University of Michigan; University of Pittsburgh; Vanderbilt University
| | - M Krummel
- Massachussets General Hospital; University of California San Francisco Comprehensive Cancer Center; Mayo Clinic, Rochester; Johns Hopkins University; University of Chicago; Georgetown; University of Indiana; University of Michigan; University of Pittsburgh; Vanderbilt University
| | - J Hwang
- Massachussets General Hospital; University of California San Francisco Comprehensive Cancer Center; Mayo Clinic, Rochester; Johns Hopkins University; University of Chicago; Georgetown; University of Indiana; University of Michigan; University of Pittsburgh; Vanderbilt University
| | - M Liu
- Massachussets General Hospital; University of California San Francisco Comprehensive Cancer Center; Mayo Clinic, Rochester; Johns Hopkins University; University of Chicago; Georgetown; University of Indiana; University of Michigan; University of Pittsburgh; Vanderbilt University
| | - BH Park
- Massachussets General Hospital; University of California San Francisco Comprehensive Cancer Center; Mayo Clinic, Rochester; Johns Hopkins University; University of Chicago; Georgetown; University of Indiana; University of Michigan; University of Pittsburgh; Vanderbilt University
| | - R Nanda
- Massachussets General Hospital; University of California San Francisco Comprehensive Cancer Center; Mayo Clinic, Rochester; Johns Hopkins University; University of Chicago; Georgetown; University of Indiana; University of Michigan; University of Pittsburgh; Vanderbilt University
| | - P Pohlmann
- Massachussets General Hospital; University of California San Francisco Comprehensive Cancer Center; Mayo Clinic, Rochester; Johns Hopkins University; University of Chicago; Georgetown; University of Indiana; University of Michigan; University of Pittsburgh; Vanderbilt University
| | - AM Storniolo
- Massachussets General Hospital; University of California San Francisco Comprehensive Cancer Center; Mayo Clinic, Rochester; Johns Hopkins University; University of Chicago; Georgetown; University of Indiana; University of Michigan; University of Pittsburgh; Vanderbilt University
| | - C Van Poznak
- Massachussets General Hospital; University of California San Francisco Comprehensive Cancer Center; Mayo Clinic, Rochester; Johns Hopkins University; University of Chicago; Georgetown; University of Indiana; University of Michigan; University of Pittsburgh; Vanderbilt University
| | - A Brufsky
- Massachussets General Hospital; University of California San Francisco Comprehensive Cancer Center; Mayo Clinic, Rochester; Johns Hopkins University; University of Chicago; Georgetown; University of Indiana; University of Michigan; University of Pittsburgh; Vanderbilt University
| | - V Abramson
- Massachussets General Hospital; University of California San Francisco Comprehensive Cancer Center; Mayo Clinic, Rochester; Johns Hopkins University; University of Chicago; Georgetown; University of Indiana; University of Michigan; University of Pittsburgh; Vanderbilt University
| | - A Wolff
- Massachussets General Hospital; University of California San Francisco Comprehensive Cancer Center; Mayo Clinic, Rochester; Johns Hopkins University; University of Chicago; Georgetown; University of Indiana; University of Michigan; University of Pittsburgh; Vanderbilt University
| | - HS Rugo
- Massachussets General Hospital; University of California San Francisco Comprehensive Cancer Center; Mayo Clinic, Rochester; Johns Hopkins University; University of Chicago; Georgetown; University of Indiana; University of Michigan; University of Pittsburgh; Vanderbilt University
| |
Collapse
|
33
|
Mayer E, DeMichele A, Gnant M, Barry W, Pfeiler G, Metzger O, Burstein H, Miller K, Rastogi P, Loibl S, Goulioti T, Zardavas D, Fesl C, Koehler M, Huang-Bartlett C, Huang X, Piccart M, Winer E, Wolff A. Abstract OT3-05-08: PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+/HER2- early breast cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-ot3-05-08] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Cell cycle inhibition is a proven target for novel cancer therapeutics. Palbociclib (P) is an orally active inhibitor of CDK4/6, and arrests the cell cycle at the G1-S transition. P in combination with endocrine therapy (ET) has demonstrated efficacy in phase II and III randomized trials for patients with newly diagnosed and recurrent hormone receptor positive/HER2 negative (HR+/HER2-) metastatic breast cancer (MBC), and is approved in these settings. Given confirmed benefits of P and ET for MBC, the PALLAS study was designed to determine if the addition of P to adjuvant ET improves outcomes over ET alone in HR+/HER2- early breast cancer.
Trial Design:
PALLAS is an international open-label phase III trial randomizing (1:1) patients (pts) to 2 years of P (125 mg daily, 21 days on 7 days off in a 28-day cycle) combined with at least 5 years of provider choice ET (AI, tamoxifen, +/- LHRH agonist), versus ET alone. The primary objective of the study is to compare invasive disease-free survival (iDFS) for the combination of P and ET, versus ET alone. Secondary objectives include comparison of iDFS excluding cancer of non-breast origin, DRFS, LRRFS, OS, as well as safety. The principal objective of the translational investigations is to determine the predictive or prognostic utility of defined genomic subgroups with respect to iDFS and OS. Additional objectives include evaluation of cfDNA and tissue biomarkers predictive of benefit or resistance, pharmacogenomics, adherence, and patient-reported QOL. Eligible pts are pre- or post-menopausal women or men with stage II-III, HR+/HER2- breast cancer. Patients may have already initiated ET, but must be randomized within 12 months of diagnosis and 6 months of initiation of adjuvant ET. Trial sample size is 4600 pts and stage IIA pts will be capped at a total accrual of 1000 pts. Interim analyses for safety, futility/efficacy and sample size re-estimation are planned. PALLAS opened in 9/2015 and accrual is ongoing. Contact information: emayer@partners.org
Key words: palbociclib, CDK4/6 inhibition, HR+/HER2- early breast cancer, adjuvant endocrine therapy.
Citation Format: Mayer E, DeMichele A, Gnant M, Barry W, Pfeiler G, Metzger O, Burstein H, Miller K, Rastogi P, Loibl S, Goulioti T, Zardavas D, Fesl C, Koehler M, Huang-Bartlett C, Huang X, Piccart M, Winer E, Wolff A. PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase 3 trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for HR+/HER2- early breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr OT3-05-08.
Collapse
Affiliation(s)
- E Mayer
- Dana Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Medical University of Vienna, Vienna, Austria; Austrian Breast&Colorectal Cancer Study Group, Vienna, Austria; UT M.D. Anderson Cancer Center, Houston, TX; Indiana University, Indianapolis, IN; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA; German Breast Group, Neu-Isenberg, Germany; Elisabeth Krankenhaus Kassel Brustzentrum, Kassel, Germany; Breast International Group, Brussels, Belgium; Pfizer, New York, NY; Johns Hopkins, Baltimore, MD; Jules Bordet Institute, Brussels, Belgium
| | - A DeMichele
- Dana Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Medical University of Vienna, Vienna, Austria; Austrian Breast&Colorectal Cancer Study Group, Vienna, Austria; UT M.D. Anderson Cancer Center, Houston, TX; Indiana University, Indianapolis, IN; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA; German Breast Group, Neu-Isenberg, Germany; Elisabeth Krankenhaus Kassel Brustzentrum, Kassel, Germany; Breast International Group, Brussels, Belgium; Pfizer, New York, NY; Johns Hopkins, Baltimore, MD; Jules Bordet Institute, Brussels, Belgium
| | - M Gnant
- Dana Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Medical University of Vienna, Vienna, Austria; Austrian Breast&Colorectal Cancer Study Group, Vienna, Austria; UT M.D. Anderson Cancer Center, Houston, TX; Indiana University, Indianapolis, IN; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA; German Breast Group, Neu-Isenberg, Germany; Elisabeth Krankenhaus Kassel Brustzentrum, Kassel, Germany; Breast International Group, Brussels, Belgium; Pfizer, New York, NY; Johns Hopkins, Baltimore, MD; Jules Bordet Institute, Brussels, Belgium
| | - W Barry
- Dana Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Medical University of Vienna, Vienna, Austria; Austrian Breast&Colorectal Cancer Study Group, Vienna, Austria; UT M.D. Anderson Cancer Center, Houston, TX; Indiana University, Indianapolis, IN; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA; German Breast Group, Neu-Isenberg, Germany; Elisabeth Krankenhaus Kassel Brustzentrum, Kassel, Germany; Breast International Group, Brussels, Belgium; Pfizer, New York, NY; Johns Hopkins, Baltimore, MD; Jules Bordet Institute, Brussels, Belgium
| | - G Pfeiler
- Dana Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Medical University of Vienna, Vienna, Austria; Austrian Breast&Colorectal Cancer Study Group, Vienna, Austria; UT M.D. Anderson Cancer Center, Houston, TX; Indiana University, Indianapolis, IN; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA; German Breast Group, Neu-Isenberg, Germany; Elisabeth Krankenhaus Kassel Brustzentrum, Kassel, Germany; Breast International Group, Brussels, Belgium; Pfizer, New York, NY; Johns Hopkins, Baltimore, MD; Jules Bordet Institute, Brussels, Belgium
| | - O Metzger
- Dana Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Medical University of Vienna, Vienna, Austria; Austrian Breast&Colorectal Cancer Study Group, Vienna, Austria; UT M.D. Anderson Cancer Center, Houston, TX; Indiana University, Indianapolis, IN; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA; German Breast Group, Neu-Isenberg, Germany; Elisabeth Krankenhaus Kassel Brustzentrum, Kassel, Germany; Breast International Group, Brussels, Belgium; Pfizer, New York, NY; Johns Hopkins, Baltimore, MD; Jules Bordet Institute, Brussels, Belgium
| | - H Burstein
- Dana Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Medical University of Vienna, Vienna, Austria; Austrian Breast&Colorectal Cancer Study Group, Vienna, Austria; UT M.D. Anderson Cancer Center, Houston, TX; Indiana University, Indianapolis, IN; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA; German Breast Group, Neu-Isenberg, Germany; Elisabeth Krankenhaus Kassel Brustzentrum, Kassel, Germany; Breast International Group, Brussels, Belgium; Pfizer, New York, NY; Johns Hopkins, Baltimore, MD; Jules Bordet Institute, Brussels, Belgium
| | - K Miller
- Dana Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Medical University of Vienna, Vienna, Austria; Austrian Breast&Colorectal Cancer Study Group, Vienna, Austria; UT M.D. Anderson Cancer Center, Houston, TX; Indiana University, Indianapolis, IN; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA; German Breast Group, Neu-Isenberg, Germany; Elisabeth Krankenhaus Kassel Brustzentrum, Kassel, Germany; Breast International Group, Brussels, Belgium; Pfizer, New York, NY; Johns Hopkins, Baltimore, MD; Jules Bordet Institute, Brussels, Belgium
| | - P Rastogi
- Dana Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Medical University of Vienna, Vienna, Austria; Austrian Breast&Colorectal Cancer Study Group, Vienna, Austria; UT M.D. Anderson Cancer Center, Houston, TX; Indiana University, Indianapolis, IN; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA; German Breast Group, Neu-Isenberg, Germany; Elisabeth Krankenhaus Kassel Brustzentrum, Kassel, Germany; Breast International Group, Brussels, Belgium; Pfizer, New York, NY; Johns Hopkins, Baltimore, MD; Jules Bordet Institute, Brussels, Belgium
| | - S Loibl
- Dana Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Medical University of Vienna, Vienna, Austria; Austrian Breast&Colorectal Cancer Study Group, Vienna, Austria; UT M.D. Anderson Cancer Center, Houston, TX; Indiana University, Indianapolis, IN; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA; German Breast Group, Neu-Isenberg, Germany; Elisabeth Krankenhaus Kassel Brustzentrum, Kassel, Germany; Breast International Group, Brussels, Belgium; Pfizer, New York, NY; Johns Hopkins, Baltimore, MD; Jules Bordet Institute, Brussels, Belgium
| | - T Goulioti
- Dana Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Medical University of Vienna, Vienna, Austria; Austrian Breast&Colorectal Cancer Study Group, Vienna, Austria; UT M.D. Anderson Cancer Center, Houston, TX; Indiana University, Indianapolis, IN; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA; German Breast Group, Neu-Isenberg, Germany; Elisabeth Krankenhaus Kassel Brustzentrum, Kassel, Germany; Breast International Group, Brussels, Belgium; Pfizer, New York, NY; Johns Hopkins, Baltimore, MD; Jules Bordet Institute, Brussels, Belgium
| | - D Zardavas
- Dana Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Medical University of Vienna, Vienna, Austria; Austrian Breast&Colorectal Cancer Study Group, Vienna, Austria; UT M.D. Anderson Cancer Center, Houston, TX; Indiana University, Indianapolis, IN; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA; German Breast Group, Neu-Isenberg, Germany; Elisabeth Krankenhaus Kassel Brustzentrum, Kassel, Germany; Breast International Group, Brussels, Belgium; Pfizer, New York, NY; Johns Hopkins, Baltimore, MD; Jules Bordet Institute, Brussels, Belgium
| | - C Fesl
- Dana Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Medical University of Vienna, Vienna, Austria; Austrian Breast&Colorectal Cancer Study Group, Vienna, Austria; UT M.D. Anderson Cancer Center, Houston, TX; Indiana University, Indianapolis, IN; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA; German Breast Group, Neu-Isenberg, Germany; Elisabeth Krankenhaus Kassel Brustzentrum, Kassel, Germany; Breast International Group, Brussels, Belgium; Pfizer, New York, NY; Johns Hopkins, Baltimore, MD; Jules Bordet Institute, Brussels, Belgium
| | - M Koehler
- Dana Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Medical University of Vienna, Vienna, Austria; Austrian Breast&Colorectal Cancer Study Group, Vienna, Austria; UT M.D. Anderson Cancer Center, Houston, TX; Indiana University, Indianapolis, IN; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA; German Breast Group, Neu-Isenberg, Germany; Elisabeth Krankenhaus Kassel Brustzentrum, Kassel, Germany; Breast International Group, Brussels, Belgium; Pfizer, New York, NY; Johns Hopkins, Baltimore, MD; Jules Bordet Institute, Brussels, Belgium
| | - C Huang-Bartlett
- Dana Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Medical University of Vienna, Vienna, Austria; Austrian Breast&Colorectal Cancer Study Group, Vienna, Austria; UT M.D. Anderson Cancer Center, Houston, TX; Indiana University, Indianapolis, IN; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA; German Breast Group, Neu-Isenberg, Germany; Elisabeth Krankenhaus Kassel Brustzentrum, Kassel, Germany; Breast International Group, Brussels, Belgium; Pfizer, New York, NY; Johns Hopkins, Baltimore, MD; Jules Bordet Institute, Brussels, Belgium
| | - X Huang
- Dana Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Medical University of Vienna, Vienna, Austria; Austrian Breast&Colorectal Cancer Study Group, Vienna, Austria; UT M.D. Anderson Cancer Center, Houston, TX; Indiana University, Indianapolis, IN; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA; German Breast Group, Neu-Isenberg, Germany; Elisabeth Krankenhaus Kassel Brustzentrum, Kassel, Germany; Breast International Group, Brussels, Belgium; Pfizer, New York, NY; Johns Hopkins, Baltimore, MD; Jules Bordet Institute, Brussels, Belgium
| | - M Piccart
- Dana Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Medical University of Vienna, Vienna, Austria; Austrian Breast&Colorectal Cancer Study Group, Vienna, Austria; UT M.D. Anderson Cancer Center, Houston, TX; Indiana University, Indianapolis, IN; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA; German Breast Group, Neu-Isenberg, Germany; Elisabeth Krankenhaus Kassel Brustzentrum, Kassel, Germany; Breast International Group, Brussels, Belgium; Pfizer, New York, NY; Johns Hopkins, Baltimore, MD; Jules Bordet Institute, Brussels, Belgium
| | - E Winer
- Dana Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Medical University of Vienna, Vienna, Austria; Austrian Breast&Colorectal Cancer Study Group, Vienna, Austria; UT M.D. Anderson Cancer Center, Houston, TX; Indiana University, Indianapolis, IN; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA; German Breast Group, Neu-Isenberg, Germany; Elisabeth Krankenhaus Kassel Brustzentrum, Kassel, Germany; Breast International Group, Brussels, Belgium; Pfizer, New York, NY; Johns Hopkins, Baltimore, MD; Jules Bordet Institute, Brussels, Belgium
| | - A Wolff
- Dana Farber Cancer Institute, Boston, MA; University of Pennsylvania, Philadelphia, PA; Medical University of Vienna, Vienna, Austria; Austrian Breast&Colorectal Cancer Study Group, Vienna, Austria; UT M.D. Anderson Cancer Center, Houston, TX; Indiana University, Indianapolis, IN; National Surgical Adjuvant Breast and Bowel Project (NSABP), Pittsburgh, PA; German Breast Group, Neu-Isenberg, Germany; Elisabeth Krankenhaus Kassel Brustzentrum, Kassel, Germany; Breast International Group, Brussels, Belgium; Pfizer, New York, NY; Johns Hopkins, Baltimore, MD; Jules Bordet Institute, Brussels, Belgium
| |
Collapse
|
34
|
Keene KS, King T, Hwang ES, Peng B, McGuire K, Tapia C, Zhang H, Bae S, Nakhlis F, Klauber-Demore N, Meszoely I, Sabel MS, Willey SC, Eterovic KA, Hudis C, Wolff A, De Los Santos J, Thompson A, Mills GB, Meric-Bernstam F. Abstract P3-04-01: Molecular determinants of post-mastectomy breast cancer recurrence. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p3-04-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction
The management of breast cancer (BC) patients who undergo mastectomy in the setting of 1-3 positive lymph nodes has been controversial. This retrospective Translational Breast Cancer Research Consortium study evaluated the molecular aberrations associated with locoregional recurrence (LRR) or distant metastasis (DM) compared to controls in an effort to identify molecular predictors associated with recurrence.
Methods/Materials
We identified 115 HER2 negative, therapy naïve, T 1-3 and N 0-1 BC patients treated with mastectomy and no post mastectomy radiation therapy from 1997 to present with available FFPE tissue blocks. The cohort included 32 patients with LRR, 34 with DM, and 49 controls (without recurrence) who were matched for stage, grade, hormone receptor status, age ≤ or > 50, chemotherapy receipt, and margin status. Matched primary and recurrent LRR samples were available for 3 patients. Hybrid capture next generation sequencing (NGS) of 142 cancer related genes and RNAseq were performed to identify DNA/RNA alterations associated with LRR or DM. The frequency of common alterations on NGS was compared with Fisher's exact test. Expression of each gene from mRNA-Seq was treated as an explanatory variable. Immunohistochemistry (IHC) was performed for PTEN, Ki-67 and cleaved caspase 3 (CC3). PTEN loss and percentage of Ki-67 and CC3 positive cells were compared between groups with Fisher's exact test and nonparametric methods, respectively.
Results
RNAseq was performed on 115 patients; there was no difference in RNA expression levels between the groups. DNA analysis was performed on 57 patients (17 LRR, 15 DM and 25 controls), NF1 mutation rate was significantly elevated in both the LRR (24%) and DM (27%) samples compared to controls 0%; (p=0.0070). The mitogen activated protein kinase (MAPK) pathway was significantly mutated in both LRR (47%) and DM (40%) samples compared to the controls 0%; (p<0.0001). There was no significant difference in the rate of alterations of the PI3K/Akt/mTOR pathway among the three groups. Of three patients with matched primary vs LRR samples, one had concordant mutations. The second patient had additional mutations in the LRR, including gain of a NF1 mutation. The third patient had complete discordance of mutations identified in primary and LRR and had gain of HER2 amplification, suggestive of a new primary. There was no significant association between the groups and the loss of PTEN expression or CC3 expression. There was a significant difference between Ki 67 positive cells in patients with LRR (mean 29%), DM (mean 26%) versus controls (mean 14%, p= 0.0011). HR+ patients were significantly more likely to have a positive PTEN, lower Ki-67 and lower CC3 expression, p=0.0004, p<0.0001, and p<0.0001 respectively.
Conclusions
In this matched cohort analysis, mutations in the MAPK pathway, specifically NF1, were associated with both LRR and DM, suggesting that alterations in this pathway are associated with a more aggressive tumor phenotype. However, there were no molecular features that discriminated between those likely to recur locally alone versus distantly. Further study is needed to validate these findings, and to determine whether targeting alterations in this pathway could decrease the risk of recurrence.
Citation Format: Keene KS, King T, Hwang ES, Peng B, McGuire K, Tapia C, Zhang H, Bae S, Nakhlis F, Klauber-Demore N, Meszoely I, Sabel MS, Willey SC, Eterovic KA, Hudis C, Wolff A, De Los Santos J, Thompson A, Mills GB, Meric-Bernstam F. Molecular determinants of post-mastectomy breast cancer recurrence [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P3-04-01.
Collapse
Affiliation(s)
- KS Keene
- University of Alabama at Birmingham, Birmingham, AL; Dana Farber Cancer Institute, Boston, MA; Duke University, Durham, NC; MD Anderson Cancer Center, Houston, TX; University of North Carolina at Chapel Hill, Chapel Hill, NC; Medical University of South Carolina, Charleston, SC; Vanderbilt University, Nashville, TN; University of Michigan, Ann Arbor, MI; Georgetown, Washington, DC; Memorial Sloan Kettering Cancer Center, New York, NY; John Hopkins University, Baltimore, MD
| | - T King
- University of Alabama at Birmingham, Birmingham, AL; Dana Farber Cancer Institute, Boston, MA; Duke University, Durham, NC; MD Anderson Cancer Center, Houston, TX; University of North Carolina at Chapel Hill, Chapel Hill, NC; Medical University of South Carolina, Charleston, SC; Vanderbilt University, Nashville, TN; University of Michigan, Ann Arbor, MI; Georgetown, Washington, DC; Memorial Sloan Kettering Cancer Center, New York, NY; John Hopkins University, Baltimore, MD
| | - ES Hwang
- University of Alabama at Birmingham, Birmingham, AL; Dana Farber Cancer Institute, Boston, MA; Duke University, Durham, NC; MD Anderson Cancer Center, Houston, TX; University of North Carolina at Chapel Hill, Chapel Hill, NC; Medical University of South Carolina, Charleston, SC; Vanderbilt University, Nashville, TN; University of Michigan, Ann Arbor, MI; Georgetown, Washington, DC; Memorial Sloan Kettering Cancer Center, New York, NY; John Hopkins University, Baltimore, MD
| | - B Peng
- University of Alabama at Birmingham, Birmingham, AL; Dana Farber Cancer Institute, Boston, MA; Duke University, Durham, NC; MD Anderson Cancer Center, Houston, TX; University of North Carolina at Chapel Hill, Chapel Hill, NC; Medical University of South Carolina, Charleston, SC; Vanderbilt University, Nashville, TN; University of Michigan, Ann Arbor, MI; Georgetown, Washington, DC; Memorial Sloan Kettering Cancer Center, New York, NY; John Hopkins University, Baltimore, MD
| | - K McGuire
- University of Alabama at Birmingham, Birmingham, AL; Dana Farber Cancer Institute, Boston, MA; Duke University, Durham, NC; MD Anderson Cancer Center, Houston, TX; University of North Carolina at Chapel Hill, Chapel Hill, NC; Medical University of South Carolina, Charleston, SC; Vanderbilt University, Nashville, TN; University of Michigan, Ann Arbor, MI; Georgetown, Washington, DC; Memorial Sloan Kettering Cancer Center, New York, NY; John Hopkins University, Baltimore, MD
| | - C Tapia
- University of Alabama at Birmingham, Birmingham, AL; Dana Farber Cancer Institute, Boston, MA; Duke University, Durham, NC; MD Anderson Cancer Center, Houston, TX; University of North Carolina at Chapel Hill, Chapel Hill, NC; Medical University of South Carolina, Charleston, SC; Vanderbilt University, Nashville, TN; University of Michigan, Ann Arbor, MI; Georgetown, Washington, DC; Memorial Sloan Kettering Cancer Center, New York, NY; John Hopkins University, Baltimore, MD
| | - H Zhang
- University of Alabama at Birmingham, Birmingham, AL; Dana Farber Cancer Institute, Boston, MA; Duke University, Durham, NC; MD Anderson Cancer Center, Houston, TX; University of North Carolina at Chapel Hill, Chapel Hill, NC; Medical University of South Carolina, Charleston, SC; Vanderbilt University, Nashville, TN; University of Michigan, Ann Arbor, MI; Georgetown, Washington, DC; Memorial Sloan Kettering Cancer Center, New York, NY; John Hopkins University, Baltimore, MD
| | - S Bae
- University of Alabama at Birmingham, Birmingham, AL; Dana Farber Cancer Institute, Boston, MA; Duke University, Durham, NC; MD Anderson Cancer Center, Houston, TX; University of North Carolina at Chapel Hill, Chapel Hill, NC; Medical University of South Carolina, Charleston, SC; Vanderbilt University, Nashville, TN; University of Michigan, Ann Arbor, MI; Georgetown, Washington, DC; Memorial Sloan Kettering Cancer Center, New York, NY; John Hopkins University, Baltimore, MD
| | - F Nakhlis
- University of Alabama at Birmingham, Birmingham, AL; Dana Farber Cancer Institute, Boston, MA; Duke University, Durham, NC; MD Anderson Cancer Center, Houston, TX; University of North Carolina at Chapel Hill, Chapel Hill, NC; Medical University of South Carolina, Charleston, SC; Vanderbilt University, Nashville, TN; University of Michigan, Ann Arbor, MI; Georgetown, Washington, DC; Memorial Sloan Kettering Cancer Center, New York, NY; John Hopkins University, Baltimore, MD
| | - N Klauber-Demore
- University of Alabama at Birmingham, Birmingham, AL; Dana Farber Cancer Institute, Boston, MA; Duke University, Durham, NC; MD Anderson Cancer Center, Houston, TX; University of North Carolina at Chapel Hill, Chapel Hill, NC; Medical University of South Carolina, Charleston, SC; Vanderbilt University, Nashville, TN; University of Michigan, Ann Arbor, MI; Georgetown, Washington, DC; Memorial Sloan Kettering Cancer Center, New York, NY; John Hopkins University, Baltimore, MD
| | - I Meszoely
- University of Alabama at Birmingham, Birmingham, AL; Dana Farber Cancer Institute, Boston, MA; Duke University, Durham, NC; MD Anderson Cancer Center, Houston, TX; University of North Carolina at Chapel Hill, Chapel Hill, NC; Medical University of South Carolina, Charleston, SC; Vanderbilt University, Nashville, TN; University of Michigan, Ann Arbor, MI; Georgetown, Washington, DC; Memorial Sloan Kettering Cancer Center, New York, NY; John Hopkins University, Baltimore, MD
| | - MS Sabel
- University of Alabama at Birmingham, Birmingham, AL; Dana Farber Cancer Institute, Boston, MA; Duke University, Durham, NC; MD Anderson Cancer Center, Houston, TX; University of North Carolina at Chapel Hill, Chapel Hill, NC; Medical University of South Carolina, Charleston, SC; Vanderbilt University, Nashville, TN; University of Michigan, Ann Arbor, MI; Georgetown, Washington, DC; Memorial Sloan Kettering Cancer Center, New York, NY; John Hopkins University, Baltimore, MD
| | - SC Willey
- University of Alabama at Birmingham, Birmingham, AL; Dana Farber Cancer Institute, Boston, MA; Duke University, Durham, NC; MD Anderson Cancer Center, Houston, TX; University of North Carolina at Chapel Hill, Chapel Hill, NC; Medical University of South Carolina, Charleston, SC; Vanderbilt University, Nashville, TN; University of Michigan, Ann Arbor, MI; Georgetown, Washington, DC; Memorial Sloan Kettering Cancer Center, New York, NY; John Hopkins University, Baltimore, MD
| | - KA Eterovic
- University of Alabama at Birmingham, Birmingham, AL; Dana Farber Cancer Institute, Boston, MA; Duke University, Durham, NC; MD Anderson Cancer Center, Houston, TX; University of North Carolina at Chapel Hill, Chapel Hill, NC; Medical University of South Carolina, Charleston, SC; Vanderbilt University, Nashville, TN; University of Michigan, Ann Arbor, MI; Georgetown, Washington, DC; Memorial Sloan Kettering Cancer Center, New York, NY; John Hopkins University, Baltimore, MD
| | - C Hudis
- University of Alabama at Birmingham, Birmingham, AL; Dana Farber Cancer Institute, Boston, MA; Duke University, Durham, NC; MD Anderson Cancer Center, Houston, TX; University of North Carolina at Chapel Hill, Chapel Hill, NC; Medical University of South Carolina, Charleston, SC; Vanderbilt University, Nashville, TN; University of Michigan, Ann Arbor, MI; Georgetown, Washington, DC; Memorial Sloan Kettering Cancer Center, New York, NY; John Hopkins University, Baltimore, MD
| | - A Wolff
- University of Alabama at Birmingham, Birmingham, AL; Dana Farber Cancer Institute, Boston, MA; Duke University, Durham, NC; MD Anderson Cancer Center, Houston, TX; University of North Carolina at Chapel Hill, Chapel Hill, NC; Medical University of South Carolina, Charleston, SC; Vanderbilt University, Nashville, TN; University of Michigan, Ann Arbor, MI; Georgetown, Washington, DC; Memorial Sloan Kettering Cancer Center, New York, NY; John Hopkins University, Baltimore, MD
| | - J De Los Santos
- University of Alabama at Birmingham, Birmingham, AL; Dana Farber Cancer Institute, Boston, MA; Duke University, Durham, NC; MD Anderson Cancer Center, Houston, TX; University of North Carolina at Chapel Hill, Chapel Hill, NC; Medical University of South Carolina, Charleston, SC; Vanderbilt University, Nashville, TN; University of Michigan, Ann Arbor, MI; Georgetown, Washington, DC; Memorial Sloan Kettering Cancer Center, New York, NY; John Hopkins University, Baltimore, MD
| | - A Thompson
- University of Alabama at Birmingham, Birmingham, AL; Dana Farber Cancer Institute, Boston, MA; Duke University, Durham, NC; MD Anderson Cancer Center, Houston, TX; University of North Carolina at Chapel Hill, Chapel Hill, NC; Medical University of South Carolina, Charleston, SC; Vanderbilt University, Nashville, TN; University of Michigan, Ann Arbor, MI; Georgetown, Washington, DC; Memorial Sloan Kettering Cancer Center, New York, NY; John Hopkins University, Baltimore, MD
| | - GB Mills
- University of Alabama at Birmingham, Birmingham, AL; Dana Farber Cancer Institute, Boston, MA; Duke University, Durham, NC; MD Anderson Cancer Center, Houston, TX; University of North Carolina at Chapel Hill, Chapel Hill, NC; Medical University of South Carolina, Charleston, SC; Vanderbilt University, Nashville, TN; University of Michigan, Ann Arbor, MI; Georgetown, Washington, DC; Memorial Sloan Kettering Cancer Center, New York, NY; John Hopkins University, Baltimore, MD
| | - F Meric-Bernstam
- University of Alabama at Birmingham, Birmingham, AL; Dana Farber Cancer Institute, Boston, MA; Duke University, Durham, NC; MD Anderson Cancer Center, Houston, TX; University of North Carolina at Chapel Hill, Chapel Hill, NC; Medical University of South Carolina, Charleston, SC; Vanderbilt University, Nashville, TN; University of Michigan, Ann Arbor, MI; Georgetown, Washington, DC; Memorial Sloan Kettering Cancer Center, New York, NY; John Hopkins University, Baltimore, MD
| |
Collapse
|
35
|
Giordano SH, Schröder CP, Poncet C, van Leeuwen-Stok E, Linderholm B, Abreu MH, Rubio I, Van Poznak C, Morganstern D, Cameron D, Vleugel MM, Smilde TJ, Bozovic-Spasojevic I, Korde L, Russell NS, den Hoed IDM, Honkoop AH, van der Velden AWG, van 't Riet M, Dijkstra N, Bogler O, Goulioti T, Hilsenbeck S, Ruddy KJ, Wolff A, van Deurzen CHM, Martens J, Bartlett JMS, Aalders K, Tryfonidis K, Cardoso F. Abstract P5-23-01: Clinical and biological characterization of male breast cancer (BC) EORTC 10085/TBCRC 029/BOOG 2013-02/BIG 2-07: Baseline results from the prospective registry. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p5-23-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND: Through the International Male Breast Cancer Program, a prospective registry for male BC was created with the goals of evaluating 1) the clinical and biological features of this disease and 2) assessing feasibility of a prospective therapeutic clinical trial.
METHODS: All men, with any stage histologically proven invasive breast cancer, age 3 18 years, and newly presenting at the participating institutions (within 3 months prior) were eligible. Patients were enrolled for 30 months after activation of the first center, through February 2017. Per the study design, if <100 men enrolled, the study would be considered a failure and therapeutic trials would not be pursued through this network. Epidemiologic data, staging, pathologic features, and BRCA status were collected. Treatment and outcome data collection is ongoing. Optional collection of FFPE tumor samples, blood, and QOL were performed in the US, the Netherlands, and Latin America. Clinical database lock for this report was May 30, 2017. We currently report patient and disease characteristics and will update with patterns of treatment for the presentation. Outcomes and biological samples will be analyzed in the future.
RESULTS: 557 patients were enrolled: 75% in Europe, 20% in United States, 5% in other countries. 6.3% of patients had missing forms. Median age was 67 years (range 26-92). 93% were diagnosed 2010-2017. Among patients with complete data, 79% presented with a breast mass. 88% were M0 and 12% M1. Among M0 patients: 47%, 39%, 2%, and 11% had T1, T2, T3, and T4 disease respectively; 52% were N0. Overall, 98% had ER+ disease and 11% had HER2+ cancer. 14% had grade 1, 56% had grade 2, and 30% had grade 3 tumors. Among 112 men who underwent BRCA1 testing, 1 was positive. Among 118 men who had BRCA2 testing, 18 (15%) were positive. 21% of men had prior or concurrent malignancies, with the following most common sites: prostate, non-melanoma skin, colorectal, and melanoma. The prevalence of previously identified possible risk factors for male breast cancer were: overweight/obesity (72%), former/current smoker (51%), current alcohol 31 drink daily (41%), family history of breast cancer (35%), gynecomastia (16%), history radiation exposure (8%), use of anti-androgens (1%), and use of estrogens (1%).
CONCLUSION: Through an international collaborative effort, we were able to prospectively accrue 557 patients to a male breast cancer registry. These results demonstrate feasibility of pursuing a therapeutic clinical trial in men with breast cancer. In addition, this study shows the relatively low uptake of BRCA testing, high rates of concurrent/prior malignancy, and the rates of potentially modifiable risk factors in this patient population.
Funding from Breast Cancer Research Foundation, Susan G. Komen, Dutch Pink Ribbon Foundation, Swedish Breast Cancer Association (BRO) and EBCC Council.
Citation Format: Giordano SH, Schröder CP, Poncet C, van Leeuwen-Stok E, Linderholm B, Abreu MH, Rubio I, Van Poznak C, Morganstern D, Cameron D, Vleugel MM, Smilde TJ, Bozovic-Spasojevic I, Korde L, Russell NS, den Hoed IDM, Honkoop AH, van der Velden AWG, van 't Riet M, Dijkstra N, Bogler O, Goulioti T, Hilsenbeck S, Ruddy KJ, Wolff A, van Deurzen CHM, Martens J, Bartlett JMS, Aalders K, Tryfonidis K, Cardoso F. Clinical and biological characterization of male breast cancer (BC) EORTC 10085/TBCRC 029/BOOG 2013-02/BIG 2-07: Baseline results from the prospective registry [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P5-23-01.
Collapse
Affiliation(s)
- SH Giordano
- The University of Texas MD Anderson Cancer Center, Houston, TX; University Medical Center Groningen, Groningen, Netherlands; EORTC HQ, Brussel, Belgium; BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, Netherlands; Sahlgrenska Academy and University Hospital, Gothenburg, Sweden; Portuguese Institute of Oncology of Porto, Porto, Portugal; Hosital General Vall D'Hebron, Barcelona, Spain; University of Michigan Health System, Ann Arbor, MI; Dana Farber Cancer Institute, Boston, MA; University of Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom; Esperanz - loc. Waterland, Netherlands; Jeroen Bosch Hospital, Den Bosch, Netherlands; Institute for Oncology and Radiology of Serbia, National Cancer Research Centre, Belgrade, Serbia; Seattle Cancer Center Alliance, Seattle; The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Elisabeth-TweeSteden Hospital, Tilburg, Netherlands; Isala Hospital, Zwolle, Netherlands; Martini Hospita
| | - CP Schröder
- The University of Texas MD Anderson Cancer Center, Houston, TX; University Medical Center Groningen, Groningen, Netherlands; EORTC HQ, Brussel, Belgium; BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, Netherlands; Sahlgrenska Academy and University Hospital, Gothenburg, Sweden; Portuguese Institute of Oncology of Porto, Porto, Portugal; Hosital General Vall D'Hebron, Barcelona, Spain; University of Michigan Health System, Ann Arbor, MI; Dana Farber Cancer Institute, Boston, MA; University of Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom; Esperanz - loc. Waterland, Netherlands; Jeroen Bosch Hospital, Den Bosch, Netherlands; Institute for Oncology and Radiology of Serbia, National Cancer Research Centre, Belgrade, Serbia; Seattle Cancer Center Alliance, Seattle; The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Elisabeth-TweeSteden Hospital, Tilburg, Netherlands; Isala Hospital, Zwolle, Netherlands; Martini Hospita
| | - C Poncet
- The University of Texas MD Anderson Cancer Center, Houston, TX; University Medical Center Groningen, Groningen, Netherlands; EORTC HQ, Brussel, Belgium; BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, Netherlands; Sahlgrenska Academy and University Hospital, Gothenburg, Sweden; Portuguese Institute of Oncology of Porto, Porto, Portugal; Hosital General Vall D'Hebron, Barcelona, Spain; University of Michigan Health System, Ann Arbor, MI; Dana Farber Cancer Institute, Boston, MA; University of Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom; Esperanz - loc. Waterland, Netherlands; Jeroen Bosch Hospital, Den Bosch, Netherlands; Institute for Oncology and Radiology of Serbia, National Cancer Research Centre, Belgrade, Serbia; Seattle Cancer Center Alliance, Seattle; The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Elisabeth-TweeSteden Hospital, Tilburg, Netherlands; Isala Hospital, Zwolle, Netherlands; Martini Hospita
| | - E van Leeuwen-Stok
- The University of Texas MD Anderson Cancer Center, Houston, TX; University Medical Center Groningen, Groningen, Netherlands; EORTC HQ, Brussel, Belgium; BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, Netherlands; Sahlgrenska Academy and University Hospital, Gothenburg, Sweden; Portuguese Institute of Oncology of Porto, Porto, Portugal; Hosital General Vall D'Hebron, Barcelona, Spain; University of Michigan Health System, Ann Arbor, MI; Dana Farber Cancer Institute, Boston, MA; University of Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom; Esperanz - loc. Waterland, Netherlands; Jeroen Bosch Hospital, Den Bosch, Netherlands; Institute for Oncology and Radiology of Serbia, National Cancer Research Centre, Belgrade, Serbia; Seattle Cancer Center Alliance, Seattle; The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Elisabeth-TweeSteden Hospital, Tilburg, Netherlands; Isala Hospital, Zwolle, Netherlands; Martini Hospita
| | - B Linderholm
- The University of Texas MD Anderson Cancer Center, Houston, TX; University Medical Center Groningen, Groningen, Netherlands; EORTC HQ, Brussel, Belgium; BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, Netherlands; Sahlgrenska Academy and University Hospital, Gothenburg, Sweden; Portuguese Institute of Oncology of Porto, Porto, Portugal; Hosital General Vall D'Hebron, Barcelona, Spain; University of Michigan Health System, Ann Arbor, MI; Dana Farber Cancer Institute, Boston, MA; University of Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom; Esperanz - loc. Waterland, Netherlands; Jeroen Bosch Hospital, Den Bosch, Netherlands; Institute for Oncology and Radiology of Serbia, National Cancer Research Centre, Belgrade, Serbia; Seattle Cancer Center Alliance, Seattle; The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Elisabeth-TweeSteden Hospital, Tilburg, Netherlands; Isala Hospital, Zwolle, Netherlands; Martini Hospita
| | - MH Abreu
- The University of Texas MD Anderson Cancer Center, Houston, TX; University Medical Center Groningen, Groningen, Netherlands; EORTC HQ, Brussel, Belgium; BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, Netherlands; Sahlgrenska Academy and University Hospital, Gothenburg, Sweden; Portuguese Institute of Oncology of Porto, Porto, Portugal; Hosital General Vall D'Hebron, Barcelona, Spain; University of Michigan Health System, Ann Arbor, MI; Dana Farber Cancer Institute, Boston, MA; University of Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom; Esperanz - loc. Waterland, Netherlands; Jeroen Bosch Hospital, Den Bosch, Netherlands; Institute for Oncology and Radiology of Serbia, National Cancer Research Centre, Belgrade, Serbia; Seattle Cancer Center Alliance, Seattle; The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Elisabeth-TweeSteden Hospital, Tilburg, Netherlands; Isala Hospital, Zwolle, Netherlands; Martini Hospita
| | - I Rubio
- The University of Texas MD Anderson Cancer Center, Houston, TX; University Medical Center Groningen, Groningen, Netherlands; EORTC HQ, Brussel, Belgium; BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, Netherlands; Sahlgrenska Academy and University Hospital, Gothenburg, Sweden; Portuguese Institute of Oncology of Porto, Porto, Portugal; Hosital General Vall D'Hebron, Barcelona, Spain; University of Michigan Health System, Ann Arbor, MI; Dana Farber Cancer Institute, Boston, MA; University of Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom; Esperanz - loc. Waterland, Netherlands; Jeroen Bosch Hospital, Den Bosch, Netherlands; Institute for Oncology and Radiology of Serbia, National Cancer Research Centre, Belgrade, Serbia; Seattle Cancer Center Alliance, Seattle; The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Elisabeth-TweeSteden Hospital, Tilburg, Netherlands; Isala Hospital, Zwolle, Netherlands; Martini Hospita
| | - C Van Poznak
- The University of Texas MD Anderson Cancer Center, Houston, TX; University Medical Center Groningen, Groningen, Netherlands; EORTC HQ, Brussel, Belgium; BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, Netherlands; Sahlgrenska Academy and University Hospital, Gothenburg, Sweden; Portuguese Institute of Oncology of Porto, Porto, Portugal; Hosital General Vall D'Hebron, Barcelona, Spain; University of Michigan Health System, Ann Arbor, MI; Dana Farber Cancer Institute, Boston, MA; University of Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom; Esperanz - loc. Waterland, Netherlands; Jeroen Bosch Hospital, Den Bosch, Netherlands; Institute for Oncology and Radiology of Serbia, National Cancer Research Centre, Belgrade, Serbia; Seattle Cancer Center Alliance, Seattle; The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Elisabeth-TweeSteden Hospital, Tilburg, Netherlands; Isala Hospital, Zwolle, Netherlands; Martini Hospita
| | - D Morganstern
- The University of Texas MD Anderson Cancer Center, Houston, TX; University Medical Center Groningen, Groningen, Netherlands; EORTC HQ, Brussel, Belgium; BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, Netherlands; Sahlgrenska Academy and University Hospital, Gothenburg, Sweden; Portuguese Institute of Oncology of Porto, Porto, Portugal; Hosital General Vall D'Hebron, Barcelona, Spain; University of Michigan Health System, Ann Arbor, MI; Dana Farber Cancer Institute, Boston, MA; University of Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom; Esperanz - loc. Waterland, Netherlands; Jeroen Bosch Hospital, Den Bosch, Netherlands; Institute for Oncology and Radiology of Serbia, National Cancer Research Centre, Belgrade, Serbia; Seattle Cancer Center Alliance, Seattle; The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Elisabeth-TweeSteden Hospital, Tilburg, Netherlands; Isala Hospital, Zwolle, Netherlands; Martini Hospita
| | - D Cameron
- The University of Texas MD Anderson Cancer Center, Houston, TX; University Medical Center Groningen, Groningen, Netherlands; EORTC HQ, Brussel, Belgium; BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, Netherlands; Sahlgrenska Academy and University Hospital, Gothenburg, Sweden; Portuguese Institute of Oncology of Porto, Porto, Portugal; Hosital General Vall D'Hebron, Barcelona, Spain; University of Michigan Health System, Ann Arbor, MI; Dana Farber Cancer Institute, Boston, MA; University of Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom; Esperanz - loc. Waterland, Netherlands; Jeroen Bosch Hospital, Den Bosch, Netherlands; Institute for Oncology and Radiology of Serbia, National Cancer Research Centre, Belgrade, Serbia; Seattle Cancer Center Alliance, Seattle; The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Elisabeth-TweeSteden Hospital, Tilburg, Netherlands; Isala Hospital, Zwolle, Netherlands; Martini Hospita
| | - MM Vleugel
- The University of Texas MD Anderson Cancer Center, Houston, TX; University Medical Center Groningen, Groningen, Netherlands; EORTC HQ, Brussel, Belgium; BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, Netherlands; Sahlgrenska Academy and University Hospital, Gothenburg, Sweden; Portuguese Institute of Oncology of Porto, Porto, Portugal; Hosital General Vall D'Hebron, Barcelona, Spain; University of Michigan Health System, Ann Arbor, MI; Dana Farber Cancer Institute, Boston, MA; University of Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom; Esperanz - loc. Waterland, Netherlands; Jeroen Bosch Hospital, Den Bosch, Netherlands; Institute for Oncology and Radiology of Serbia, National Cancer Research Centre, Belgrade, Serbia; Seattle Cancer Center Alliance, Seattle; The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Elisabeth-TweeSteden Hospital, Tilburg, Netherlands; Isala Hospital, Zwolle, Netherlands; Martini Hospita
| | - TJ Smilde
- The University of Texas MD Anderson Cancer Center, Houston, TX; University Medical Center Groningen, Groningen, Netherlands; EORTC HQ, Brussel, Belgium; BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, Netherlands; Sahlgrenska Academy and University Hospital, Gothenburg, Sweden; Portuguese Institute of Oncology of Porto, Porto, Portugal; Hosital General Vall D'Hebron, Barcelona, Spain; University of Michigan Health System, Ann Arbor, MI; Dana Farber Cancer Institute, Boston, MA; University of Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom; Esperanz - loc. Waterland, Netherlands; Jeroen Bosch Hospital, Den Bosch, Netherlands; Institute for Oncology and Radiology of Serbia, National Cancer Research Centre, Belgrade, Serbia; Seattle Cancer Center Alliance, Seattle; The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Elisabeth-TweeSteden Hospital, Tilburg, Netherlands; Isala Hospital, Zwolle, Netherlands; Martini Hospita
| | - I Bozovic-Spasojevic
- The University of Texas MD Anderson Cancer Center, Houston, TX; University Medical Center Groningen, Groningen, Netherlands; EORTC HQ, Brussel, Belgium; BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, Netherlands; Sahlgrenska Academy and University Hospital, Gothenburg, Sweden; Portuguese Institute of Oncology of Porto, Porto, Portugal; Hosital General Vall D'Hebron, Barcelona, Spain; University of Michigan Health System, Ann Arbor, MI; Dana Farber Cancer Institute, Boston, MA; University of Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom; Esperanz - loc. Waterland, Netherlands; Jeroen Bosch Hospital, Den Bosch, Netherlands; Institute for Oncology and Radiology of Serbia, National Cancer Research Centre, Belgrade, Serbia; Seattle Cancer Center Alliance, Seattle; The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Elisabeth-TweeSteden Hospital, Tilburg, Netherlands; Isala Hospital, Zwolle, Netherlands; Martini Hospita
| | - L Korde
- The University of Texas MD Anderson Cancer Center, Houston, TX; University Medical Center Groningen, Groningen, Netherlands; EORTC HQ, Brussel, Belgium; BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, Netherlands; Sahlgrenska Academy and University Hospital, Gothenburg, Sweden; Portuguese Institute of Oncology of Porto, Porto, Portugal; Hosital General Vall D'Hebron, Barcelona, Spain; University of Michigan Health System, Ann Arbor, MI; Dana Farber Cancer Institute, Boston, MA; University of Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom; Esperanz - loc. Waterland, Netherlands; Jeroen Bosch Hospital, Den Bosch, Netherlands; Institute for Oncology and Radiology of Serbia, National Cancer Research Centre, Belgrade, Serbia; Seattle Cancer Center Alliance, Seattle; The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Elisabeth-TweeSteden Hospital, Tilburg, Netherlands; Isala Hospital, Zwolle, Netherlands; Martini Hospita
| | - NS Russell
- The University of Texas MD Anderson Cancer Center, Houston, TX; University Medical Center Groningen, Groningen, Netherlands; EORTC HQ, Brussel, Belgium; BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, Netherlands; Sahlgrenska Academy and University Hospital, Gothenburg, Sweden; Portuguese Institute of Oncology of Porto, Porto, Portugal; Hosital General Vall D'Hebron, Barcelona, Spain; University of Michigan Health System, Ann Arbor, MI; Dana Farber Cancer Institute, Boston, MA; University of Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom; Esperanz - loc. Waterland, Netherlands; Jeroen Bosch Hospital, Den Bosch, Netherlands; Institute for Oncology and Radiology of Serbia, National Cancer Research Centre, Belgrade, Serbia; Seattle Cancer Center Alliance, Seattle; The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Elisabeth-TweeSteden Hospital, Tilburg, Netherlands; Isala Hospital, Zwolle, Netherlands; Martini Hospita
| | - IDM den Hoed
- The University of Texas MD Anderson Cancer Center, Houston, TX; University Medical Center Groningen, Groningen, Netherlands; EORTC HQ, Brussel, Belgium; BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, Netherlands; Sahlgrenska Academy and University Hospital, Gothenburg, Sweden; Portuguese Institute of Oncology of Porto, Porto, Portugal; Hosital General Vall D'Hebron, Barcelona, Spain; University of Michigan Health System, Ann Arbor, MI; Dana Farber Cancer Institute, Boston, MA; University of Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom; Esperanz - loc. Waterland, Netherlands; Jeroen Bosch Hospital, Den Bosch, Netherlands; Institute for Oncology and Radiology of Serbia, National Cancer Research Centre, Belgrade, Serbia; Seattle Cancer Center Alliance, Seattle; The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Elisabeth-TweeSteden Hospital, Tilburg, Netherlands; Isala Hospital, Zwolle, Netherlands; Martini Hospita
| | - AH Honkoop
- The University of Texas MD Anderson Cancer Center, Houston, TX; University Medical Center Groningen, Groningen, Netherlands; EORTC HQ, Brussel, Belgium; BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, Netherlands; Sahlgrenska Academy and University Hospital, Gothenburg, Sweden; Portuguese Institute of Oncology of Porto, Porto, Portugal; Hosital General Vall D'Hebron, Barcelona, Spain; University of Michigan Health System, Ann Arbor, MI; Dana Farber Cancer Institute, Boston, MA; University of Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom; Esperanz - loc. Waterland, Netherlands; Jeroen Bosch Hospital, Den Bosch, Netherlands; Institute for Oncology and Radiology of Serbia, National Cancer Research Centre, Belgrade, Serbia; Seattle Cancer Center Alliance, Seattle; The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Elisabeth-TweeSteden Hospital, Tilburg, Netherlands; Isala Hospital, Zwolle, Netherlands; Martini Hospita
| | - AWG van der Velden
- The University of Texas MD Anderson Cancer Center, Houston, TX; University Medical Center Groningen, Groningen, Netherlands; EORTC HQ, Brussel, Belgium; BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, Netherlands; Sahlgrenska Academy and University Hospital, Gothenburg, Sweden; Portuguese Institute of Oncology of Porto, Porto, Portugal; Hosital General Vall D'Hebron, Barcelona, Spain; University of Michigan Health System, Ann Arbor, MI; Dana Farber Cancer Institute, Boston, MA; University of Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom; Esperanz - loc. Waterland, Netherlands; Jeroen Bosch Hospital, Den Bosch, Netherlands; Institute for Oncology and Radiology of Serbia, National Cancer Research Centre, Belgrade, Serbia; Seattle Cancer Center Alliance, Seattle; The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Elisabeth-TweeSteden Hospital, Tilburg, Netherlands; Isala Hospital, Zwolle, Netherlands; Martini Hospita
| | - M van 't Riet
- The University of Texas MD Anderson Cancer Center, Houston, TX; University Medical Center Groningen, Groningen, Netherlands; EORTC HQ, Brussel, Belgium; BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, Netherlands; Sahlgrenska Academy and University Hospital, Gothenburg, Sweden; Portuguese Institute of Oncology of Porto, Porto, Portugal; Hosital General Vall D'Hebron, Barcelona, Spain; University of Michigan Health System, Ann Arbor, MI; Dana Farber Cancer Institute, Boston, MA; University of Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom; Esperanz - loc. Waterland, Netherlands; Jeroen Bosch Hospital, Den Bosch, Netherlands; Institute for Oncology and Radiology of Serbia, National Cancer Research Centre, Belgrade, Serbia; Seattle Cancer Center Alliance, Seattle; The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Elisabeth-TweeSteden Hospital, Tilburg, Netherlands; Isala Hospital, Zwolle, Netherlands; Martini Hospita
| | - N Dijkstra
- The University of Texas MD Anderson Cancer Center, Houston, TX; University Medical Center Groningen, Groningen, Netherlands; EORTC HQ, Brussel, Belgium; BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, Netherlands; Sahlgrenska Academy and University Hospital, Gothenburg, Sweden; Portuguese Institute of Oncology of Porto, Porto, Portugal; Hosital General Vall D'Hebron, Barcelona, Spain; University of Michigan Health System, Ann Arbor, MI; Dana Farber Cancer Institute, Boston, MA; University of Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom; Esperanz - loc. Waterland, Netherlands; Jeroen Bosch Hospital, Den Bosch, Netherlands; Institute for Oncology and Radiology of Serbia, National Cancer Research Centre, Belgrade, Serbia; Seattle Cancer Center Alliance, Seattle; The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Elisabeth-TweeSteden Hospital, Tilburg, Netherlands; Isala Hospital, Zwolle, Netherlands; Martini Hospita
| | - O Bogler
- The University of Texas MD Anderson Cancer Center, Houston, TX; University Medical Center Groningen, Groningen, Netherlands; EORTC HQ, Brussel, Belgium; BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, Netherlands; Sahlgrenska Academy and University Hospital, Gothenburg, Sweden; Portuguese Institute of Oncology of Porto, Porto, Portugal; Hosital General Vall D'Hebron, Barcelona, Spain; University of Michigan Health System, Ann Arbor, MI; Dana Farber Cancer Institute, Boston, MA; University of Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom; Esperanz - loc. Waterland, Netherlands; Jeroen Bosch Hospital, Den Bosch, Netherlands; Institute for Oncology and Radiology of Serbia, National Cancer Research Centre, Belgrade, Serbia; Seattle Cancer Center Alliance, Seattle; The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Elisabeth-TweeSteden Hospital, Tilburg, Netherlands; Isala Hospital, Zwolle, Netherlands; Martini Hospita
| | - T Goulioti
- The University of Texas MD Anderson Cancer Center, Houston, TX; University Medical Center Groningen, Groningen, Netherlands; EORTC HQ, Brussel, Belgium; BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, Netherlands; Sahlgrenska Academy and University Hospital, Gothenburg, Sweden; Portuguese Institute of Oncology of Porto, Porto, Portugal; Hosital General Vall D'Hebron, Barcelona, Spain; University of Michigan Health System, Ann Arbor, MI; Dana Farber Cancer Institute, Boston, MA; University of Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom; Esperanz - loc. Waterland, Netherlands; Jeroen Bosch Hospital, Den Bosch, Netherlands; Institute for Oncology and Radiology of Serbia, National Cancer Research Centre, Belgrade, Serbia; Seattle Cancer Center Alliance, Seattle; The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Elisabeth-TweeSteden Hospital, Tilburg, Netherlands; Isala Hospital, Zwolle, Netherlands; Martini Hospita
| | - S Hilsenbeck
- The University of Texas MD Anderson Cancer Center, Houston, TX; University Medical Center Groningen, Groningen, Netherlands; EORTC HQ, Brussel, Belgium; BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, Netherlands; Sahlgrenska Academy and University Hospital, Gothenburg, Sweden; Portuguese Institute of Oncology of Porto, Porto, Portugal; Hosital General Vall D'Hebron, Barcelona, Spain; University of Michigan Health System, Ann Arbor, MI; Dana Farber Cancer Institute, Boston, MA; University of Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom; Esperanz - loc. Waterland, Netherlands; Jeroen Bosch Hospital, Den Bosch, Netherlands; Institute for Oncology and Radiology of Serbia, National Cancer Research Centre, Belgrade, Serbia; Seattle Cancer Center Alliance, Seattle; The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Elisabeth-TweeSteden Hospital, Tilburg, Netherlands; Isala Hospital, Zwolle, Netherlands; Martini Hospita
| | - KJ Ruddy
- The University of Texas MD Anderson Cancer Center, Houston, TX; University Medical Center Groningen, Groningen, Netherlands; EORTC HQ, Brussel, Belgium; BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, Netherlands; Sahlgrenska Academy and University Hospital, Gothenburg, Sweden; Portuguese Institute of Oncology of Porto, Porto, Portugal; Hosital General Vall D'Hebron, Barcelona, Spain; University of Michigan Health System, Ann Arbor, MI; Dana Farber Cancer Institute, Boston, MA; University of Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom; Esperanz - loc. Waterland, Netherlands; Jeroen Bosch Hospital, Den Bosch, Netherlands; Institute for Oncology and Radiology of Serbia, National Cancer Research Centre, Belgrade, Serbia; Seattle Cancer Center Alliance, Seattle; The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Elisabeth-TweeSteden Hospital, Tilburg, Netherlands; Isala Hospital, Zwolle, Netherlands; Martini Hospita
| | - A Wolff
- The University of Texas MD Anderson Cancer Center, Houston, TX; University Medical Center Groningen, Groningen, Netherlands; EORTC HQ, Brussel, Belgium; BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, Netherlands; Sahlgrenska Academy and University Hospital, Gothenburg, Sweden; Portuguese Institute of Oncology of Porto, Porto, Portugal; Hosital General Vall D'Hebron, Barcelona, Spain; University of Michigan Health System, Ann Arbor, MI; Dana Farber Cancer Institute, Boston, MA; University of Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom; Esperanz - loc. Waterland, Netherlands; Jeroen Bosch Hospital, Den Bosch, Netherlands; Institute for Oncology and Radiology of Serbia, National Cancer Research Centre, Belgrade, Serbia; Seattle Cancer Center Alliance, Seattle; The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Elisabeth-TweeSteden Hospital, Tilburg, Netherlands; Isala Hospital, Zwolle, Netherlands; Martini Hospita
| | - CHM van Deurzen
- The University of Texas MD Anderson Cancer Center, Houston, TX; University Medical Center Groningen, Groningen, Netherlands; EORTC HQ, Brussel, Belgium; BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, Netherlands; Sahlgrenska Academy and University Hospital, Gothenburg, Sweden; Portuguese Institute of Oncology of Porto, Porto, Portugal; Hosital General Vall D'Hebron, Barcelona, Spain; University of Michigan Health System, Ann Arbor, MI; Dana Farber Cancer Institute, Boston, MA; University of Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom; Esperanz - loc. Waterland, Netherlands; Jeroen Bosch Hospital, Den Bosch, Netherlands; Institute for Oncology and Radiology of Serbia, National Cancer Research Centre, Belgrade, Serbia; Seattle Cancer Center Alliance, Seattle; The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Elisabeth-TweeSteden Hospital, Tilburg, Netherlands; Isala Hospital, Zwolle, Netherlands; Martini Hospita
| | - J Martens
- The University of Texas MD Anderson Cancer Center, Houston, TX; University Medical Center Groningen, Groningen, Netherlands; EORTC HQ, Brussel, Belgium; BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, Netherlands; Sahlgrenska Academy and University Hospital, Gothenburg, Sweden; Portuguese Institute of Oncology of Porto, Porto, Portugal; Hosital General Vall D'Hebron, Barcelona, Spain; University of Michigan Health System, Ann Arbor, MI; Dana Farber Cancer Institute, Boston, MA; University of Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom; Esperanz - loc. Waterland, Netherlands; Jeroen Bosch Hospital, Den Bosch, Netherlands; Institute for Oncology and Radiology of Serbia, National Cancer Research Centre, Belgrade, Serbia; Seattle Cancer Center Alliance, Seattle; The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Elisabeth-TweeSteden Hospital, Tilburg, Netherlands; Isala Hospital, Zwolle, Netherlands; Martini Hospita
| | - JMS Bartlett
- The University of Texas MD Anderson Cancer Center, Houston, TX; University Medical Center Groningen, Groningen, Netherlands; EORTC HQ, Brussel, Belgium; BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, Netherlands; Sahlgrenska Academy and University Hospital, Gothenburg, Sweden; Portuguese Institute of Oncology of Porto, Porto, Portugal; Hosital General Vall D'Hebron, Barcelona, Spain; University of Michigan Health System, Ann Arbor, MI; Dana Farber Cancer Institute, Boston, MA; University of Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom; Esperanz - loc. Waterland, Netherlands; Jeroen Bosch Hospital, Den Bosch, Netherlands; Institute for Oncology and Radiology of Serbia, National Cancer Research Centre, Belgrade, Serbia; Seattle Cancer Center Alliance, Seattle; The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Elisabeth-TweeSteden Hospital, Tilburg, Netherlands; Isala Hospital, Zwolle, Netherlands; Martini Hospita
| | - K Aalders
- The University of Texas MD Anderson Cancer Center, Houston, TX; University Medical Center Groningen, Groningen, Netherlands; EORTC HQ, Brussel, Belgium; BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, Netherlands; Sahlgrenska Academy and University Hospital, Gothenburg, Sweden; Portuguese Institute of Oncology of Porto, Porto, Portugal; Hosital General Vall D'Hebron, Barcelona, Spain; University of Michigan Health System, Ann Arbor, MI; Dana Farber Cancer Institute, Boston, MA; University of Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom; Esperanz - loc. Waterland, Netherlands; Jeroen Bosch Hospital, Den Bosch, Netherlands; Institute for Oncology and Radiology of Serbia, National Cancer Research Centre, Belgrade, Serbia; Seattle Cancer Center Alliance, Seattle; The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Elisabeth-TweeSteden Hospital, Tilburg, Netherlands; Isala Hospital, Zwolle, Netherlands; Martini Hospita
| | - K Tryfonidis
- The University of Texas MD Anderson Cancer Center, Houston, TX; University Medical Center Groningen, Groningen, Netherlands; EORTC HQ, Brussel, Belgium; BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, Netherlands; Sahlgrenska Academy and University Hospital, Gothenburg, Sweden; Portuguese Institute of Oncology of Porto, Porto, Portugal; Hosital General Vall D'Hebron, Barcelona, Spain; University of Michigan Health System, Ann Arbor, MI; Dana Farber Cancer Institute, Boston, MA; University of Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom; Esperanz - loc. Waterland, Netherlands; Jeroen Bosch Hospital, Den Bosch, Netherlands; Institute for Oncology and Radiology of Serbia, National Cancer Research Centre, Belgrade, Serbia; Seattle Cancer Center Alliance, Seattle; The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Elisabeth-TweeSteden Hospital, Tilburg, Netherlands; Isala Hospital, Zwolle, Netherlands; Martini Hospita
| | - F Cardoso
- The University of Texas MD Anderson Cancer Center, Houston, TX; University Medical Center Groningen, Groningen, Netherlands; EORTC HQ, Brussel, Belgium; BOOG Study Center/Dutch Breast Cancer Research Group, Amsterdam, Netherlands; Sahlgrenska Academy and University Hospital, Gothenburg, Sweden; Portuguese Institute of Oncology of Porto, Porto, Portugal; Hosital General Vall D'Hebron, Barcelona, Spain; University of Michigan Health System, Ann Arbor, MI; Dana Farber Cancer Institute, Boston, MA; University of Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom; Esperanz - loc. Waterland, Netherlands; Jeroen Bosch Hospital, Den Bosch, Netherlands; Institute for Oncology and Radiology of Serbia, National Cancer Research Centre, Belgrade, Serbia; Seattle Cancer Center Alliance, Seattle; The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Elisabeth-TweeSteden Hospital, Tilburg, Netherlands; Isala Hospital, Zwolle, Netherlands; Martini Hospita
| |
Collapse
|
36
|
Abstract
SummaryThe HL7 Clinical Document Architecture (CDA) is an important XML-based standard for the representation of clinical documents.
Objectives:
The use of Markup Languages could satisfy the demands of involved healthcare staff as well as the needs of patients, to receive an overview of the patient’s treatment during the hospital stay. The standardization efforts of different groups dealing with this problem have demonstrated progress, but have not, as yet, achieved a routinely usable result. In particular, differentiating information according to a hierarchical order has not been published to date.
Methods:
A retrospective analysis of 60 discharge letters from a cardiology ward (ward A) as well as 60 discharge letters from a gastroenterology ward (ward B) were extracted from the central hospital information system, by taking every fifth discharge letter issued over a one year period.
Results:
An XML-based prototype for medical discharge letters has been put in place representing the required information units and information elements. By means of an XSL-stylesheet, a detailed representation of the conventional discharge letter has been produced that is platform independent and permits the recurrent use of information units.
Conclusions:
Through the introduction of definitions like information elements and information units, progress in the development of CDA level two and three might be realized. We present a method by which discharge letters can be used by an Internal Medicine Department. This concept is implemented in a XML-based prototype allowing a special view on XML data to generate this document type.
Collapse
|
37
|
Paulitschke M, Mall J, Büttemeyer R, Meyer R, Wolff A, Rademacher A. Vascular PTFE Grafts Endothelialised under Defined Flow: From in Vitro Data to Clinical Use. Int J Artif Organs 2018. [DOI: 10.1177/039139880202500735] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
| | - J. Mall
- Charité Medical School, Berlin
| | | | | | - A. Wolff
- BioTissue Technologies, Freiburg - Germany
| | | |
Collapse
|
38
|
Lambertini M, Campbell C, Bines J, Korde L, Izquierdo Delso M, Fumagalli D, Pritchard K, Wolff A, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Barrios C, Baselga J, Moreno-Aspitia A, Piccart M, Gelber R, De Azambuja E. Adjuvant anti-HER2 therapy, treatment-induced amenorrhea (TIA) and survival in premenopausal patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Analysis from the ALTTO trial (BIG 2-06). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx362.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
39
|
Lukosius M, Dabrowski J, Kitzmann J, Fursenko O, Akhtar F, Lisker M, Lippert G, Schulze S, Yamamoto Y, Schubert MA, Krause HM, Wolff A, Mai A, Schroeder T, Lupina G. Metal-Free CVD Graphene Synthesis on 200 mm Ge/Si(001) Substrates. ACS Appl Mater Interfaces 2016; 8:33786-33793. [PMID: 27960421 DOI: 10.1021/acsami.6b11397] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
Good quality, complementary-metal-oxide-semiconductor (CMOS) technology compatible, 200 mm graphene was obtained on Ge(001)/Si(001) wafers in this work. Chemical vapor depositions were carried out at the deposition temperatures of 885 °C using CH4 as carbon source on epitaxial Ge(100) layers, which were grown on Si(100), prior to the graphene synthesis. Graphene layer with the 2D/G ratio ∼3 and low D mode (i.e., low concentration of defects) was measured over the entire 200 mm wafer by Raman spectroscopy. A typical full-width-at-half-maximum value of 39 cm-1 was extracted for the 2D mode, further indicating that graphene of good structural quality was produced. The study also revealed that the lack of interfacial oxide correlates with superior properties of graphene. In order to evaluate electrical properties of graphene, its 2 × 2 cm2 pieces were transferred onto SiO2/Si substrates from Ge/Si wafers. The extracted sheet resistance and mobility values of transferred graphene layers were ∼1500 ± 100 Ω/sq and μ ≈ 400 ± 20 cm2/V s, respectively. The transferred graphene was free of metallic contaminations or mechanical damage. On the basis of results of DFT calculations, we attribute the high structural quality of graphene grown by CVD on Ge to hydrogen-induced reduction of nucleation probability, explain the appearance of graphene-induced facets on Ge(001) as a kinetic effect caused by surface step pinning at linear graphene nuclei, and clarify the orientation of graphene domains on Ge(001) as resulting from good lattice matching between Ge(001) and graphene nucleated on such nuclei.
Collapse
Affiliation(s)
- M Lukosius
- IHP , Im Technologiepark 25, 15236 Frankfurt (Oder), Germany
| | - J Dabrowski
- IHP , Im Technologiepark 25, 15236 Frankfurt (Oder), Germany
| | - J Kitzmann
- IHP , Im Technologiepark 25, 15236 Frankfurt (Oder), Germany
| | - O Fursenko
- IHP , Im Technologiepark 25, 15236 Frankfurt (Oder), Germany
| | - F Akhtar
- IHP , Im Technologiepark 25, 15236 Frankfurt (Oder), Germany
| | - M Lisker
- IHP , Im Technologiepark 25, 15236 Frankfurt (Oder), Germany
| | - G Lippert
- IHP , Im Technologiepark 25, 15236 Frankfurt (Oder), Germany
| | - S Schulze
- IHP , Im Technologiepark 25, 15236 Frankfurt (Oder), Germany
| | - Y Yamamoto
- IHP , Im Technologiepark 25, 15236 Frankfurt (Oder), Germany
| | - M A Schubert
- IHP , Im Technologiepark 25, 15236 Frankfurt (Oder), Germany
| | - H M Krause
- IHP , Im Technologiepark 25, 15236 Frankfurt (Oder), Germany
| | - A Wolff
- IHP , Im Technologiepark 25, 15236 Frankfurt (Oder), Germany
| | - A Mai
- IHP , Im Technologiepark 25, 15236 Frankfurt (Oder), Germany
| | - T Schroeder
- IHP , Im Technologiepark 25, 15236 Frankfurt (Oder), Germany
- BTU Cottbus-Senftenberg , Konrad Zuse Str. 1, 03046 Cottbus, Germany
| | - G Lupina
- IHP , Im Technologiepark 25, 15236 Frankfurt (Oder), Germany
| |
Collapse
|
40
|
Muglia C, Nagella N, Wolff A. P113 Congenital bronchial atresia mimicking asthma and causing a 28 year delay in correct diagnosis. Ann Allergy Asthma Immunol 2016. [DOI: 10.1016/j.anai.2016.09.123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
41
|
Canali C, Mazzoni C, Larsen LB, Heiskanen A, Martinsen ØG, Wolff A, Dufva M, Emnéus J. An impedance method for spatial sensing of 3D cell constructs--towards applications in tissue engineering. Analyst 2016. [PMID: 26198701 DOI: 10.1039/c5an00987a] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
We present the characterisation and validation of multiplexed 4-terminal (4T) impedance measurements as a method for sensing the spatial location of cell aggregates within large three-dimensional (3D) gelatin scaffolds. The measurements were performed using an array of four rectangular chambers, each having eight platinum needle electrodes for parallel analysis. The electrode positions for current injection and voltage measurements were optimised by means of finite element simulations to maximise the sensitivity field distribution and spatial resolution. Eight different 4T combinations were experimentally tested in terms of the spatial sensitivity. The simulated sensitivity fields were validated using objects (phantoms) with different conductivity and size placed in different positions inside the chamber. This provided the detection limit (volume sensitivity) of 16.5%, i.e. the smallest detectable volume with respect to the size of the measurement chamber. Furthermore, the possibility for quick single frequency analysis was demonstrated by finding a common frequency of 250 kHz for all the presented electrode combinations. As final proof of concept, a high density of human hepatoblastoma (HepG2) cells were encapsulated in gelatin to form artificial 3D cell constructs and detected when placed in different positions inside large gelatin scaffolds. Taken together, these results open new perspectives for impedance-based sensing technologies for non-invasive monitoring in tissue engineering applications providing spatial information of constructs within biologically relevant 3D environments.
Collapse
Affiliation(s)
- C Canali
- Department of Micro- and Nanotechnology, Technical University of Denmark, 2800, Kgs. Lyngby, Denmark.
| | | | | | | | | | | | | | | |
Collapse
|
42
|
Villa A, Wolff A, Narayana N, Dawes C, Aframian DJ, Lynge Pedersen AM, Vissink A, Aliko A, Sia YW, Joshi RK, McGowan R, Jensen SB, Kerr AR, Ekström J, Proctor G. World Workshop on Oral Medicine VI: a systematic review of medication-induced salivary gland dysfunction. Oral Dis 2016; 22:365-82. [PMID: 26602059 DOI: 10.1111/odi.12402] [Citation(s) in RCA: 55] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2015] [Revised: 11/11/2015] [Accepted: 11/14/2015] [Indexed: 12/11/2022]
Abstract
The aim of this paper was to perform a systematic review of the pathogenesis of medication-induced salivary gland dysfunction (MISGD). Review of the identified papers was based on the standards regarding the methodology for systematic reviews set forth by the World Workshop on Oral Medicine IV and the PRISMA statement. Eligible papers were assessed for both the degree and strength of relevance to the pathogenesis of MISGD as well as on the appropriateness of the study design and sample size. A total of 99 papers were retained for the final analysis. MISGD in human studies was generally reported as xerostomia (the sensation of oral dryness) without measurements of salivary secretion rate. Medications may act on the central nervous system (CNS) and/or at the neuroglandular junction on muscarinic, α-and β-adrenergic receptors and certain peptidergic receptors. The types of medications that were most commonly implicated for inducing salivary gland dysfunction were those acting on the nervous, cardiovascular, genitourinary, musculoskeletal, respiratory, and alimentary systems. Although many medications may affect the salivary flow rate and composition, most of the studies considered only xerostomia. Thus, further human studies are necessary to improve our understanding of the association between MISGD and the underlying pathophysiology.
Collapse
Affiliation(s)
- A Villa
- Division of Oral Medicine and Dentistry, Brigham and Women's Hospital, Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, MA, USA
| | - A Wolff
- Tel-Aviv Sourasky Medical Center and Saliwell Ltd., Harutzim, Israel
| | - N Narayana
- Department of Oral Biology, UNMC College of Dentistry, Lincoln, NE, USA
| | - C Dawes
- Department of Oral Biology, University of Manitoba, Winnipeg, MB, Canada
| | | | - A M Lynge Pedersen
- Department of Odontology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - A Vissink
- University of Groningen and University Medical Center Groningen, Groningen, The Netherlands
| | - A Aliko
- Faculty of Dental Medicine, University of Medicine, Tirana, Albania.,Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway
| | - Y W Sia
- McGill University, Montreal, QC, Canada
| | - R K Joshi
- DAPMRV Dental College, Bangalore, India
| | - R McGowan
- New York University College of Dentistry, New York, NY, USA
| | - S B Jensen
- Department of Odontology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - A R Kerr
- New York University College of Dentistry, New York, NY, USA
| | - J Ekström
- Department of Pharmacology, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden
| | - G Proctor
- Division of Mucosal & Salivary Biology, Dental Institute, King's College London, London, UK
| |
Collapse
|
43
|
Wilson L, Gross J, Gallagher G, Wolff A. Comparing trends in the use and outcomes of non invasive ventilation (NIV) in a general intensive care unit. Intensive Care Med Exp 2015. [PMCID: PMC4797481 DOI: 10.1186/2197-425x-3-s1-a675] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
44
|
Kozlovsky A, Wolff A, Saminsky M, Mazor Y, Venezia E, Bar-Ness Greenstein R. Effect ofAggregatibacter actinomycetemcomitansfrom Aggressive Periodontitis patients onStreptococcus mutans. Oral Dis 2015; 21:955-61. [DOI: 10.1111/odi.12362] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2014] [Revised: 06/24/2015] [Accepted: 07/30/2015] [Indexed: 11/26/2022]
Affiliation(s)
- A Kozlovsky
- Department of Periodontology and Implant Dentistry; The Maurice and Gabriela Goldschleger School of Dental Medicine; Tel Aviv University; Tel Aviv Israel
| | - A Wolff
- Department of Oral & Maxillofacial Surgery; Rambam Health Care Campus; Haifa Israel
| | - M Saminsky
- Department of Periodontology; Rambam Health Care Campus; Haifa Israel
| | - Y Mazor
- Department of Oral Biology; The Maurice and Gabriela Goldschleger School of Dental Medicine; Tel Aviv University; Tel Aviv Israel
| | - E Venezia
- Periodontology Unit; Department of Oral & Maxillofacial Surgery; Rabin Medical Center; Beilinson Campus; Petach Tikva Israel
| | - R Bar-Ness Greenstein
- Department of Oral Biology; The Maurice and Gabriela Goldschleger School of Dental Medicine; Tel Aviv University; Tel Aviv Israel
| |
Collapse
|
45
|
Shantsila E, Wolff A, Lip GYH, Lane DA. Gender differences in stroke prevention in atrial fibrillation in general practice: using the GRASP-AF audit tool. Int J Clin Pract 2015; 69:840-5. [PMID: 25752615 DOI: 10.1111/ijcp.12625] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
BACKGROUND Women represent a large proportion of patients with atrial fibrillation (AF) and tend to have higher risk of stroke. AIMS This study examines gender differences in the utilisation of oral anticoagulation (OAC) and prognosis (i.e. stroke and death) in AF patients in UK general practice. DESIGN Retrospective observational study. METHODS The Guidance on Risk Assessment and Stroke Prevention in Atrial Fibrillation (GRASP-AF) tool was employed to identify AF patients from 11 general practices in Darlington, England. RESULTS Two thousand two hundred and fifty-nine AF patients (mean±SD age 76 ± 12 years; 46% female) were identified. Based on CHA2 DS2 -VASc score 95% of women and 90% of men were at moderate-high risk of stroke. Women with moderate-high risk of stroke were treated with OAC less frequently than men (47% vs. 52%, p = 0.006). Overall rates of stroke and all-cause mortality were higher among women than men (p = 0.02 and p < 0.001). However, there was no significant gender difference in these outcomes in patients receiving OAC (p = 0.52 for stroke, p = 0.18 for death). Among people not receiving OAC where indicated, female gender was associated with an increased risk of stroke before (p = 0.01), and after (p = 0.04), adjustment for stroke risk factors. Women not receiving OAC had a higher risk of death on univariate regression analysis (p = 0.002), but not after adjustment for stroke risk factors (p = 0.53). CONCLUSION Women with AF are at higher risk of stroke than men without OAC. The gender-related differences in risk of stroke disappear if OAC is used. Despite this, women are more likely not to receive OAC.
Collapse
Affiliation(s)
- E Shantsila
- University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK
| | - A Wolff
- Whinfield Medical Practice, Darlington, UK
| | - G Y H Lip
- University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK
| | - D A Lane
- University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK
| |
Collapse
|
46
|
Dawes C, Pedersen A, Villa A, Ekström J, Proctor G, Vissink A, Aframian D, McGowan R, Aliko A, Narayana N, Sia Y, Joshi R, Jensen S, Kerr A, Wolff A. The functions of human saliva: A review sponsored by the World Workshop on Oral Medicine VI. Arch Oral Biol 2015; 60:863-74. [DOI: 10.1016/j.archoralbio.2015.03.004] [Citation(s) in RCA: 249] [Impact Index Per Article: 27.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2014] [Revised: 02/28/2015] [Accepted: 03/02/2015] [Indexed: 12/22/2022]
|
47
|
Jatoi A, Muss H, Allred JB, Cohen HJ, Ballman K, Hopkins JO, Gajra A, Lafky J, Wolff A, Kottschade L, Gralow J, Hurria A. Social support and its implications in older, early-stage breast cancer patients in CALGB 49907 (Alliance A171301). Psychooncology 2015; 25:441-6. [PMID: 25994447 DOI: 10.1002/pon.3850] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2014] [Revised: 03/23/2015] [Accepted: 04/14/2015] [Indexed: 01/19/2023]
Abstract
BACKGROUND Studies point to a direct association between social support and better cancer outcomes. This study examined whether baseline social support is associated with better survival and fewer chemotherapy-related adverse events in older, early-stage breast cancer patients. METHODS This study is a pre-planned secondary analysis of CALGB 49907/Alliance A171301, a randomized trial that compared standard adjuvant chemotherapy versus capecitabine in breast cancer patients 65 years of age or older. A subset reported on the extent of their social support with questionnaires that were completed 6 times over 2 years. RESULTS The median age of this 331-patient cohort was 72 years (range: 65, 90); 179 (55%) were married, and 210 (65%) lived with someone. One hundred forty-five patients (46%) described a social network of 0-10 people; 110 (35%) of 11-25; and 58 (19%) of 26 or more. The Medical Outcomes Study (MOS) social support survey revealed that the median scores (range) for emotional/informational, tangible, positive social interaction, and affectionate social support were 94 (3, 100), 94 (0, 100), 96 (0, 100), and 100 (8, 100), respectively. Social support scores appeared stable over 2 years and higher (more support) than in other cancer settings. No statistically significant associations were observed between social support and survival and adverse events in multivariate analyses. However, married patients had smaller tumors, and those with arthritis reported less social support. CONCLUSION Although social support did not predict survival and adverse events, the exploratory but plausible inverse associations with larger tumors and arthritis suggest that social support merits further study.
Collapse
Affiliation(s)
- Aminah Jatoi
- Department of Oncology, Mayo Clinic, Rochester, MN, USA
| | - Hyman Muss
- University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA
| | - Jake B Allred
- Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN, USA
| | - Harvey J Cohen
- Department of Medicine and Center for the Study of Aging and Human Development, Duke University, Durham, NC, USA
| | - Karla Ballman
- Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN, USA
| | | | - Ajeet Gajra
- Department of Medicine, State University of New York Upstate Medical University, Syracuse, NY, USA
| | - Jacqueline Lafky
- Cancer Center Clinical Research Offices, Mayo Clinic, Rochester, MN, USA
| | - Antonio Wolff
- Department of Oncology, Johns Hopkins University, Baltimore, MD, USA
| | | | - Julie Gralow
- Division of Medical Oncology, University of Washington, Seattle, WA, USA
| | | |
Collapse
|
48
|
Rütten A, Wolff A, Streber A. [Sustainable Implementation of Evidence-Based Programmes in Health Promotion: A Theoretical Framework and Concept of Interactive Knowledge to Action]. Gesundheitswesen 2015; 78:139-45. [PMID: 25985226 DOI: 10.1055/s-0035-1548883] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
OBJECTIVES This article discusses 2 current issues in the field of public health research: (i) transfer of scientific knowledge into practice and (ii) sustainable implementation of good practice projects. It also supports integration of scientific and practice-based evidence production. Furthermore, it supports utilisation of interactive models that transcend deductive approaches to the process of knowledge transfer. METHODS Existing theoretical approaches, pilot studies and thoughtful conceptual considerations are incorporated into a framework showing the interplay of science, politics and prevention practice, which fosters a more sustainable implementation of health promotion programmes. The framework depicts 4 key processes of interaction between science and prevention practice: interactive knowledge to action, capacity building, programme adaptation and adaptation of the implementation context. RESULTS Ensuring sustainability of health promotion programmes requires a concentrated process of integrating scientific and practice-based evidence production in the context of implementation. Central to the integration process is the approach of interactive knowledge to action, which especially benefits from capacity building processes that facilitate participation and systematic interaction between relevant stakeholders. Intense cooperation also induces a dynamic interaction between multiple actors and components such as health promotion programmes, target groups, relevant organisations and social, cultural and political contexts. The reciprocal adaptation of programmes and key components of the implementation context can foster effectiveness and sustainability of programmes. CONCLUSION Sustainable implementation of evidence-based health promotion programmes requires alternatives to recent deductive models of knowledge transfer. Interactive approaches prove to be promising alternatives. Simultaneously, they change the responsibilities of science, policy and public health practice. Existing boundaries within disciplines and sectors are overcome by arranging transdisciplinary teams as well as by developing common agendas and procedures. Such approaches also require adaptations of the structure of research projects such as extending the length of funding.
Collapse
Affiliation(s)
- A Rütten
- Institut für Sportwissenschaft und Sport, Friedrich-Alexander-Universität Erlangen-Nürnberg
| | - A Wolff
- Institut für Sportwissenschaft und Sport, Friedrich-Alexander-Universität Erlangen-Nürnberg
| | - A Streber
- Institut für Sportwissenschaft und Sport, Friedrich-Alexander-Universität Erlangen-Nürnberg
| |
Collapse
|
49
|
Rütten A, Wolff A, Streber A. [Interactive Knowledge to Action in Health Promotion: The GESTALT Project. Initial Results of a Pilot Study on Sustainable Implementation of an Evidence-Based Programme]. Gesundheitswesen 2015; 78:359-66. [PMID: 25985225 DOI: 10.1055/s-0035-1548882] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
OBJECTIVES The present article outlines a pilot study to demonstrate the concept of the interactive knowledge to action approach in order to foster sustainable implementation of an evidence-based physical activity programme for dementia prevention into practice. The approach and procedures will be introduced, and initial results of the pilot study "GESTALT", with special regard to the interplay of science, politics and prevention practice, will be outlined. METHODS In the GESTALT project (2011-2014) the concept of interactive knowledge to action was realised through a cooperative planning approach that systematically engaged and involved stakeholders from science, politics and practice. Evaluation of the project's sustainability focused on 3 dimensions: target group, organisations and context. Target group analysis included assessment of changes in physical activity behaviour (n=75). Organisational and context evaluations included an analysis of relevant documentation of cooperative planning meetings, conduction of the programme, bilateral talks and further meetings. RESULTS In relation to the target group, the majority of participants (60%) were committed to an active lifestyle 6 months after completion of the GESTALT programme. Regarding organisations and context, 14 partner organisations maintained active engagement in cooperative planning processes. After adapting the GESTALT programme to the context and needs of the organisations and participants, 5 organisations were able to implement it. These same organisations also continued to provide exercise classes for ex-participants of the initial GESTALT programme. Through developing partnerships, increasing publicity and attracting policy makers, resources for the sustainable implementation of the GESTALT project were obtained. CONCLUSION The pilot study GESTALT shows that the concept of interactive knowledge to action has substantially contributed to the sustainability of a physical activity programme in the field of dementia prevention. For this purpose changes in local structures, as well as adaptations of the GESTALT programme to the existing structures of prevention practice had to be made. The approach of cooperative planning proved to be appropriate for the generation of knowledge in terms of practice-based evidence, and it favoured the reciprocal adaptation of the GESTALT programme and implementation contexts.
Collapse
Affiliation(s)
- A Rütten
- Institut für Sportwissenschaft und Sport, Friedrich-Alexander-Universität Erlangen-Nürnberg
| | - A Wolff
- Institut für Sportwissenschaft und Sport, Friedrich-Alexander-Universität Erlangen-Nürnberg
| | - A Streber
- Institut für Sportwissenschaft und Sport, Friedrich-Alexander-Universität Erlangen-Nürnberg
| |
Collapse
|
50
|
Kistrup K, Poulsen CE, Hansen MF, Wolff A. Ultrasonic welding for fast bonding of self-aligned structures in lab-on-a-chip systems. Lab Chip 2015; 15:1998-2001. [PMID: 25806857 DOI: 10.1039/c5lc00174a] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Ultrasonic welding is a rapid, promising bonding method for the bonding of polymer chips; yet its use is still limited. We present two lab-on-a-chip applications where ultrasonic welding can be preferably applied: (1) self-aligned gapless bonding of a two-part chip with a tolerance of 50 μm; (2) bonding of a large area shallow chamber (1.8 cm(2) × 150 μm). Using injection moulding combined with ultrasonic welding we achieved a total production and bonding time of 60 s per chip, and a batch of chips could be produced within a day going from design to finished chips. We believe that the technical solutions offered here can significantly help bridge the gap between academia and industry, where the differences in production methods and materials pose a challenge when transferring technology.
Collapse
Affiliation(s)
- K Kistrup
- Department of Micro- and Nanotechnology, Technical University of Denmark, DTU Nanotech, Building 345 East, DK-2800 Kongens Lyngby, Denmark.
| | | | | | | |
Collapse
|